Clinical trial register · Spain

Clinical Trials in Madrid, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in Madrid

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Active, closed

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

NCT05583227Eosinophilic Esophagitis

DrugTezepelumab

AstraZeneca

Phase 3

368

Barcelona, Madrid, Pamplona, Seville, Tomelloso

2022-11-10

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020Multiple Myeloma

DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide

Pfizer

Phase 3

1,060

Santiago de Compostela, Badalona, L'Hospitalet Del Llobregat, Terrassa, Santander, Barcelona, Girona, Madrid

2022-11-10

Active, closed

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257Cystic Fibrosis

DrugVNZ/TEZ/D-IVA

Vertex Pharmaceuticals Incorporated

Phase 3

822

Barcelona, Madrid, Murcia, Sabadell, Seville, Valencia

2022-11-08

Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283Chronic Kidney Disease, Proteinuria, Children

DrugFinerenone

Bayer

Phase 3

100

Esplugues de Llobregat, Barcelona, Madrid, Málaga, Seville

2022-11-08

Active, closed

The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

NCT05374291Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure, Kidney Failure

DrugDapagliflozin

University Medical Center Groningen

Phase 3

1,750

Barcelona, Lleida, Madrid, Palma de Mallorca, Pamplona, Valencia

2022-11-08

Active, closed

Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer

NCT05384015Small Cell Lung Cancer Extensive Stage

DrugsLenvatinib·Etoposide·Keytruda·Carboplatin

Fundación GECP

Phase 2

Alicante, Badalona, Barcelona, Bilbao, Girona, A Coruña, Lugo, Madrid

2022-11-07

Active, closed

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

NCT05490446Myelodysplastic Syndromes

DrugTebapivat

Agios Pharmaceuticals, Inc.

Phase 2

Córdoba, Madrid, Salamanca, Seville

2022-11-07

Active, closed

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

NCT05614102Advanced Solid Tumors

DrugPembrolizumab

Bayer

Phase 1

284

Pamplona, Barcelona, Madrid

2022-11-04

Active, closed

Impact of a Risk Stratification Tool on the Outcome of Liver Transplant Recipients Colonized With Carbapenem Resistant Enterobacteriaceae: an Observational Study

NCT05594901Liver Transplantation, Carbapenem-Resistant Enterobacteriaceae Colonization

University of Bologna

Observational

240

Madrid

2022-11-01

Active, closed

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

NCT05567796Obesity

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

3,400

Pamplona, Barcelona, Castilleja de la Cuesta, León, Madrid, Seville

2022-11-01

Recruiting

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

NCT05363280Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung

DrugAL8326

Advenchen Pharmaceuticals, LLC.

Phase 2

Barcelona, Madrid

2022-11-01

Active, closed

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

NCT04020055Fabry Disease

DrugMigalastat HCl

Amicus Therapeutics

Phase 3

Barcelona, Elda, Madrid

2022-10-31

Recruiting

A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting

NCT05452941Pneumonia

Pfizer

Observational

12,500

L'Hospitalet de Llobregat, Getafe, Leganés, Vigo, Valencia, Barcelona, Madrid, Málaga

2022-10-27

Active, closed

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05169515Non-Hodgkin Lymphoma

DrugsGolcadomide·Iberdomide·Mosunetuzumab·Glofitamab

Hoffmann-La Roche

Phase 1

121

L'Hospitalet de Llobregat, Valencia, Barcelona, Madrid, Salamanca

2022-10-26

Active, closed

Berotralstat Treatment in Children With Hereditary Angioedema

NCT05453968Hereditary Angioedema, Pediatric

DrugBerotralstat

BioCryst Pharmaceuticals

Phase 3

Madrid, Málaga

2022-10-25

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Badalona, Barcelona, Granada, Jerez de la Frontera, Madrid, Palma de Mallorca, Pozuelo de Alarcón, Salamanca

2022-10-25

Recruiting

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms

DrugsPF-08046054·Keytruda·Pembrolizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 1

714

Barcelona, Madrid

2022-10-25

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651Colorectal Neoplasms

DrugsTucatinib·Herceptin·Erbitux·Avastin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

400

L'Hospitalet de Llobregat, Barcelona, San Cristóbal de La Laguna, Alicante, Córdoba, Lleida, Madrid, Málaga

2022-10-24

Active, closed

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT05358249KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer

DrugsOpnurasib·Trametinib·Ribociclib·Cetuximab

Novartis Pharmaceuticals

Phase 1/2

Barcelona, Madrid

2022-10-24

Recruiting

Clinical Trial of Infusion of Activated NK Cells for the Treatment of Sarcomas

NCT05952310Malignant Sarcoma

Antonio Pérez Martínez

Not applicable

Madrid

2022-10-24

Active, closed

A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp

NCT05387525Keratosis, Actinic

DrugDiclofenac Sodium

Almirall, S.A.

Phase 4

447

Barcelona, Granada, Madrid, Salamanca, Seville, Valencia, Zaragoza

2022-10-24

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05259839Relapsed/Refractory Multiple Myeloma

DrugsEtentamig·Pomalidomide·Daratumumab·Lenalidomide

AbbVie

Phase 1

283

L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Seville

2022-10-20

Recruiting

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

NCT05547321Advanced Solid Tumor

DrugsOMTX705·Tislelizumab·Pembrolizumab

Oncomatryx Biopharma S.L.

Phase 1

150

Barcelona, L'Hospitalet de Llobregat, Santiago de Compostela, San Sebastián, Madrid, Pamplona

2022-10-20

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05581004Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma

DrugsTecentriq·Atezolizumab·Keytruda·Pembrolizumab

Genentech, Inc.

Phase 1

165

L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia

2022-10-20

Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

NCT05372354Multiple Myeloma

DrugsBMS-986158·Tazemetostat·Mezigdomide·Trametinib

Bristol-Myers Squibb

Phase 1/2

260

Barcelona, Madrid, Santander

2022-10-18

Active, closed

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05559359Atopic Dermatitis, Eczema

DrugLebrikizumab

Eli Lilly and Company

Phase 3

377

Esplugues de Llobregat, Las, Madrid, Pamplona

2022-10-18

Active, closed

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

NCT05620134Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer

DrugsLenvatinib Pill·Pembrolizumab

Salubris Biotherapeutics Inc

Phase 1/2

263

Barcelona, Madrid, Valencia

2022-10-17

Active, closed

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

NCT05535244Multiple Myeloma

DrugsCevostamab·Tocilizumab

Hoffmann-La Roche

Phase 1/2

Barcelona, Madrid

2022-10-17

Active, closed

A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)

NCT05981092Cardiomyopathy, Dilated, Bcl-2 Anathogene-3 (BAG3) Dilated Cardiomyopathy (DCM)

Alexion Pharmaceuticals, Inc.

Observational

A Coruña, Madrid, Majadahonda, El Palmar

2022-10-14

Active, closed

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

NCT05565378Lung Cancer, Non-Small Cell

DrugsNelistotug·Belrestotug·Dostarlimab·Pembrolizumab

GlaxoSmithKline

Phase 2

351

Badajoz, Badalona, Barcelona, Las Palmas de Gran Canar, Madrid, Málaga, PamplonaNavarra, Valencia

2022-10-14

Active, closed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes

Bayer

Phase 3

474

Santiago de Compostela, Aravaca, Barcelona, Granada, Madrid, Seville, Valencia

2022-10-14

Active, closed

Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura

NCT05046717Acquired Thrombotic Thrombocytopenic Purpura

Fundación Española de Hematología y Hemoterapía

Observational

500

A Coruña, Barcelona, Madrid, Valencia

2022-10-13

Recruiting

International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder

NCT05590715Autism Spectrum Disorder

Stalicla SA

Observational

1,500

Alicante, Barcelona, Madrid, Majadahonda, San Sebastián, Vigo

2022-10-13

Active, closed

Optilume Registry for Treatment of Stricture of the Anterior Urethra

NCT05479422Anterior Urethral Stricture, Male

European Association of Urology Research Foundation

Observational

150

Santander, Madrid, Pamplona

2022-10-13

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Badalona, Barcelona, El Palmar, Jerez de la Frontera, León, Madrid, Málaga, Pamplona

2022-10-13

Active, closed

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05502237Non-small Cell Lung Cancer

DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed

Gilead Sciences

Phase 3

1,021

Barcelona, Córdoba, Girona, Jaén, Las Palmas de Gran Canaria, Madrid, Majadahonda, Reus

2022-10-12

Recruiting

Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs.

NCT05635929Oral Mucositis, Quality of Life, Mucositis, Pain

Mucosa Innovations, S.L.

Not applicable

Madrid

2022-10-11

Active, closed

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

NCT05537740Advanced Solid Tumors

DrugPembrolizumab

Bayer

Phase 1

129

Pamplona, Barcelona, Madrid

2022-10-11

Active, closed

Aerobic Exercise and Resistant Hypertension

NCT05563077Resistant Hypertension

Universidad Europea de Madrid

Not applicable

Madrid

2022-10-05

Active, closed

Utility of CYP2D6 Genotyping to Improve the Efficacy and Safety of Tramadol

NCT05657704Post-surgical Pain, Pain, Acute, Postoperative Pain

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Phase 4

300

Majadahonda, Alicante, Burgos, Madrid

2022-10-05

Recruiting

Met Non Small Cell Cancer Registry (MOMENT)

NCT05376891Cancer

EMD Serono Research & Development Institute, Inc.

Observational

700

Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Seville, Valencia

2022-10-04

Active, closed

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

NCT05206357Non-hodgkin Lymphoma

DrugEpcoritamab

Genmab

Phase 1

Barcelona, Esplugues de Llobregat, Madrid

2022-10-04

Active, closed

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

NCT05453903Leukemia, Myeloid, Acute

DrugsBleximenib·Idarubicin·Daunorubicin·Cytarabine

Janssen Research & Development, LLC

Phase 1

196

Barcelona, Madrid, Pamplona

2022-10-04

Recruiting

Study of the Role of Genetic Modifiers in Hemoglobinopathies

NCT05799118Sickle Cell Disease, Thalassemia, Beta, Thalassemia Alpha, Hemoglobinopathies

Cyprus Institute of Neurology and Genetics

Observational

30,000

Madrid

2022-10-01

Recruiting

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

NCT05183035Acute Myeloid Leukemia

DrugsGemtuzumab Ozogamicin·Cytarabine·Azacitidine·Fludarabine

PedAL BCU, LLC

Phase 3

130

Barcelona, Madrid, Valencia

2022-10-01

Recruiting

Keeping RAASi Treatment With Optimal Potassium Control

NCT06578533Chronic Kidney Diseases

DrugSodium Zirconium Cyclosilicate

Fundación para la Investigación del Hospital Clínico de Valencia

Phase 3

Alicante, Barcelona, Madrid, Valencia

2022-09-30

Active, closed

Observational Study in Patients With Cyclin-dependent Kinase-like 5 Deficiency Disorder

NCT05373719Cyclin-Dependent Kinase-Like 5 Deficiency Disorder

Loulou Foundation

Observational

112

Madrid

2022-09-30

Recruiting

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

NCT05443126NSCLC

DrugPemetrexed

Ellipses Pharma

Phase 1/2

265

A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga

2022-09-30

Recruiting

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

NCT05476939Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered

DrugsDordaviprone·Everolimus

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

433

Barcelona, Madrid, Valencia

2022-09-29

Active, closed

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

NCT05456685High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

DrugsMIRV·Mirvetuximab Soravtansine·Carboplatin

AbbVie

Phase 2

125

A Coruña, Badalona, Córdoba, Pamplona, Badajoz, Barcelona, Lleida, Madrid

2022-09-28

Recruiting

Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5

NCT05544864Coronary Artery Disease, Restenoses, Coronary

Deutsches Herzzentrum Muenchen

Not applicable

376

Madrid

2022-09-28

Active, closed

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease

DrugGuselkumab

Janssen-Cilag Ltd.

Phase 3

288

Barcelona, Ferrol, Girona, Madrid, Majadahonda, Seville, Vigo, Zaragoza

2022-09-27

Recruiting

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

201

Alicante, Barcelona, Bilbao, Donostia / San Sebastian, Madrid, Seville

2022-09-23

Active, closed

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

NCT05371093Relapsed/Refractory Follicular Lymphoma

DrugsAxi-cel·Axicabtagene Ciloleucel·Bendamustine·Vincristine

Kite, A Gilead Company

Phase 3

231

Barcelona, Madrid, Salamanca, Seville, Valencia

2022-09-22

Active, closed

The Euro-CRAFT Registry

NCT05805462Coronary Microvascular Disease

CoreAalst BV

Observational

671

Cadiz, Madrid

2022-09-22

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

NCT05409066Follicular Lymphoma (FL)

DrugsEpcoritamab·Lenalidomide·Rituximab

Genmab

Phase 3

549

Badalona, L'Hospitalet de Llobregat, Santander, Córdoba, Pamplona, Barcelona, Cáceres, Madrid

2022-09-20

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib

Celgene

Phase 3

810

Palma, Barcelona, Murcia, Marbella, Cáceres, León, Madrid

2022-09-20

Active, closed

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

NCT05440786Sarcoma, Ewing, Neoplasm Metastasis

DrugsAbemaciclib·Temozolomide·Irinotecan

Eli Lilly and Company

Phase 2

Barcelona, Esplugues de Llobregat, Madrid, Seville, Valencia

2022-09-20

Active, closed

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor

DrugElironrasib

Revolution Medicines, Inc.

Phase 1

222

Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Seville, Zaragoza

2022-09-19

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484Colitis, Ulcerative

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

577

Barcelona, Madrid, Pamplona, Pontevedra, Sabadell, Santander, Torrejón de Ardoz, Vigo

2022-09-19

Active, closed

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsCeralasertib·Durvalumab·Docetaxel

AstraZeneca

Phase 3

594

A Coruña, Barcelona, Castellon, Córdoba, Hospitalet deLlobregat, Madrid, Málaga, Ourense

2022-09-15

Active, closed

XIENCE Skypoint Large Vessel Post Approval Study

NCT05423379Coronary Artery Disease

Abbott Medical Devices

Observational

102

Madrid, Santander, Seville

2022-09-14

Active, closed

Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration

NCT04796545AMD, Age-Related Macular Degeneration

VisionCare, Inc.

Not applicable

Alicante, Barcelona, Madrid

2022-09-13

Recruiting

Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis

NCT04098146Mandibular Reconstruction, Segmental Mandibular Defects

AO Innovation Translation Center

Observational

300

Madrid

2022-09-12

Active, closed

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

NCT05570058IPF, Fibrosis

Redx Pharma Ltd

Phase 2

Barcelona, Madrid, Oviedo, Santander, Santiago de Compostela

2022-09-08

Active, closed

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

NCT05425940Colorectal Cancer

DrugsZanzalintinib·Regorafenib·Tecentriq·Atezolizumab

Exelixis

Phase 3

901

Barcelona, Lleida, Madrid, Valencia, Zaragoza

2022-09-07

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

454

Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville

2022-09-06

Recruiting

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

NCT05334368Hypereosinophilic Syndrome

DrugDepemokimab

GlaxoSmithKline

Phase 3

109

Barcelona, Granada, Madrid, Pozuelo de AlarcOn Madr, Salamanca, Valencia, Zaragoza

2022-09-06

By invitation

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis

DrugTreprostinil

United Therapeutics

Phase 3

1,850

Santiago de Compostela, Palma de Mallorca, L'Hospitalet de Llobregat, Málaga, Oviedo, Barcelona, Granada, Madrid

2022-09-06

By invitation

Outcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment

NCT05825898Tricuspid Regurgitation

Ottawa Heart Institute Research Corporation

Observational

3,500

Madrid

2022-09-01

Recruiting

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

NCT05533697Advanced Solid Tumors

DrugsIpilimumab·Nivolumab·Pembrolizumab

ModernaTX, Inc.

Phase 1/2

361

Logroño, Barcelona, Madrid, Málaga

2022-09-01

Recruiting

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms

DrugsElacestrant·Abemaciclib

Stemline Therapeutics, Inc.

Phase 1/2

Córdoba, Madrid, El Palmar, Barcelona, Pamplona, Santiago de Compostela, Valencia

2022-08-31

Recruiting

Prevention of Incisional Hernia After Renal Transplantation

NCT04794582Incisional Hernia, Kidney Transplantation, Postoperative Complications

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Not applicable

160

Madrid

2022-08-31

Recruiting

Asciminib Roll-over Study

NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 4

347

Santiago Compostela, Badalona, L'Hospitalet de Llobregat, Bilbao, Santa Cruz, Barcelona, Madrid, Seville

2022-08-30

Recruiting

Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears

NCT05444465Rotator Cuff Injuries

Smith & Nephew, Inc.

Not applicable

234

Madrid

2022-08-30

Recruiting

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

NCT05548296Endometrial Adenocarcinoma

DrugGemcitabine

Acrivon Therapeutics

Phase 2

350

Barcelona, Madrid, Valencia

2022-08-29

Active, closed

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

NCT05500222NASH, Cirrhosis, Liver

DrugResmetirom

Madrigal Pharmaceuticals, Inc.

Phase 3

845

Majadahonda, Barcelona, Madrid, Seville

2022-08-26

Active, closed

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05361395Extensive Stage Small Cell Lung Cancer

DrugsTarlatamab·Tecentriq·Etoposide·Atezolizumab

Amgen

Phase 1

184

Badalona, Barcelona, Madrid

2022-08-24

Active, closed

Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers

NCT04936685Meningococcal Immunisation, Healthy Volunteers

Sanofi Pasteur, a Sanofi Company

Phase 3

209

Santiago de Compostela, Madrid, Seville

2022-08-23

Recruiting

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

NCT05511363Psychosis Associated With Alzheimer's Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

410

Barcelona, Madrid, Salamanca, Seville, Valladolid, Zamora, Zaragoza

2022-08-23

Active, closed

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

NCT05327530Locally Advanced or Metastatic Urothelial Carcinoma

DrugsAvelumab·Sacituzumab Govitecan

EMD Serono Research & Development Institute, Inc.

Phase 2

256

Badajoz, Barcelona, Córdoba, Elche, Lugo, Madrid, Manresa

2022-08-17

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

NCT05137054Multiple Myeloma

DrugsNirogacestat·Cevostamab·Fianlimab·Linvoseltamab

Regeneron Pharmaceuticals

Phase 1

317

Santiago de Compostela, Badalona, Santander, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid, Salamanca

2022-08-17

Recruiting

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

NCT05489705Obstructive Hypertrophic Cardiomyopathy

DrugMavacamten

Bristol-Myers Squibb

Observational

1,700

Palma de Mallorca, Majadahonda, El Palmar, Oviedo, Burgos, Madrid, Málaga

2022-08-16

Active, closed

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

NCT05502341HIV-1-infection

DrugsBictegravir·Lenacapavir

Gilead Sciences

Phase 2/3

689

Barcelona, Madrid, Seville

2022-08-16

Active, closed

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05421663Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Janssen Research & Development, LLC

Phase 1/2

166

Barcelona, Madrid

2022-08-12

Active, closed

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

NCT05061134Melanoma

DrugsCeralasertib·Durvalumab

AstraZeneca

Phase 2

194

Barcelona, Madrid, Málaga, Pamplona, Pozuelo de Alarcón

2022-08-11

Recruiting

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

NCT05268289Lupus Nephritis

DrugIptacopan

Novartis Pharmaceuticals

Phase 2

240

Port de Sagunt, Barcelona, Ciudad Real, Madrid, Seville

2022-08-10

Active, closed

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

NCT05371080Herpes Zoster

GlaxoSmithKline

Phase 3

3,038

Balenyà (Barcelona), Barcelona, Centelles (Barcelona), La Roca del Vallès, Madrid, Majadahonda( Madrid, Marid, Peralada( Girona)

2022-08-10

Recruiting

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV

DrugsAbraxane·Nab-paclitaxel·Gemcitabine

Panbela Therapeutics, Inc.

Phase 2/3

600

Badalona, Santander, Jaén, Barcelona, Madrid, El Palmar, Pamplona, Barakaldo

2022-08-08

Active, closed

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer

DrugsLazertinib·Amivantamab

Janssen Research & Development, LLC

Phase 3

418

A Coruña, Alicante, Barcelona, Córdoba, Las Palmas de Gran Canaria, Lugo, Madrid, Majadahonda

2022-08-05

Active, closed

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214Sjogren Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

506

Santander, Vigo, Barcelona, Córdoba, Madrid, Valencia

2022-08-04

Active, closed

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

NCT05464030Colorectal Cancer

DrugsM9140·Folinic acid·Adrucil·Capecitabine

EMD Serono Research & Development Institute, Inc.

Phase 1

220

Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville

2022-08-04

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Tamoxifen·Exemestane·Everolimus

Genentech, Inc.

Phase 3

373

A Coruña, Barcelona, Córdoba, Madrid, Murcia, Valencia

2022-08-03

Active, closed

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

NCT05261399Carcinoma, Non-Small-Cell Lung

DrugsSavolitinib·Tagrisso·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

341

Badajoz, Badalona, Barcelona, Córdoba, Girona, Madrid, Majadahonda, Málaga

2022-08-03

Active, closed

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

NCT05297448Hepatic Encephalopathy

DrugRifaximin SSD

Bausch Health Americas, Inc.

Phase 3

466

Barcelona, Madrid, Málaga, Pontevedra, Valencia, Zaragoza

2022-08-03

Recruiting

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

NCT05410145KRAS P.G12C

DrugsD3S-001·Cetuximab·Pemetrexed·Cisplatin

D3 Bio (Wuxi) Co., Ltd

Phase 1/2

442

Barcelona, Madrid, Valencia

2022-08-03

Recruiting

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

NCT05379595Advanced or Metastatic Colorectal Cancer

DrugsAmivantamab·Fluorouracil·Leucovorin·Irinotecan

Janssen Research & Development, LLC

Phase 1/2

225

Barcelona, Madrid, Santander, Valencia

2022-07-29

Active, closed

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286Triple Negative Breast Cancer, PD-L1 Positive

DrugsAbraxane·Sacituzumab Govitecan·Taxol·Nab-paclitaxel

Gilead Sciences

Phase 3

443

A Coruña, Barcelona, Bilbao, Lleida, Madrid, Málaga, Murcia, Santa Cruz de Tenerife

2022-07-25

Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

DrugsPirtobrutinib·Ibrutinib

Loxo Oncology, Inc.

Phase 3

737

Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Marbella, Pamplona, Santander, Seville

2022-07-22

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471Crohn's Disease

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

703

Madrid, Pamplona, Pontevedra, Sabadell, Santander, Torrejón de Ardoz

2022-07-22

Active, closed

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

NCT05371613Mucopolysaccharidosis II

DrugsIdursulfase·Tividenofusp alfa

Denali Therapeutics Inc.

Phase 2/3

Barcelona, Madrid

2022-07-21

Active, closed

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

DrugsZilovertamab vedotin·Nemtabrutinib

Merck Sharp & Dohme LLC

Phase 2

189

L'Hospitalet Del Llobregat, Barcelona, Madrid, Pamplona, Salamanca

2022-07-21

Active, closed

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382299Triple Negative Breast Cancer, PD-L1 Negative

DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine

Gilead Sciences

Phase 3

623

A Coruña, Barcelona, Bilbao, Lleida, Madrid, Murcia, Seville, Valencia

2022-07-20

Recruiting

Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS

NCT05451784Metastatic Triple-Negative Breast Carcinoma

DrugSerplulimab

Fundacio Clinic Barcelona

Phase 1/2

Barcelona, Madrid, Pamplona

2022-07-20

Active, closed

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

NCT05222555Diffuse Large B Cell Lymphoma

DrugsTafasitamab·Lenalidomide

Incyte Corporation

Phase 1/2

Palma de Mallorca, Girona, L'Hospitalet de Llobregat, Madrid, Salamanca, Seville, Valencia

2022-07-19

Active, closed

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

NCT05296798Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Phesgo·Pertuzumab·Trastuzumab

Hoffmann-La Roche

Phase 3

922

Sant Andreu de la Barca, Santiago de Compostela, San Cristóbal de La Laguna, Barcelona, Granada, Huelva, Madrid, Málaga

2022-07-18

Active, closed

Assess Safety and Efficacy of VAD044 in HHT Patients

NCT05406362Hereditary Hemorrhagic Telangiectasia (HHT)

DrugEngasertib

Vaderis Therapeutics AG

Phase 1/2

Barcelona, Madrid

2022-07-18

Active, closed

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

NCT05406401Lymphoma, Large B-Cell, Diffuse (DLBCL)

DrugsRituximab Biosimilar·Zilovertamab vedotin·Truxima·Adriamycin

Merck Sharp & Dohme LLC

Phase 2

Seville, L'Hospitalet Del Llobregat, Madrid

2022-07-14

Active, closed

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

NCT05126277Lupus Nephritis

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

452

Santiago Compostela, Pamplona, Vigo, San Cristóbal de La Laguna, Valencia, Barcelona, Madrid

2022-07-14

Active, closed

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

NCT05392114Hereditary Angioedema

DrugDonidalorsen

Ionis Pharmaceuticals, Inc.

Phase 3

154

Barcelona, Madrid, Seville, Valencia

2022-07-13

Active, closed

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

NCT05142696Extensive Stage Small Cell Lung Cancer

Drugs[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Lutathera·Atezolizumab

Novartis Pharmaceuticals

Phase 1/2

Barcelona, Madrid, Málaga

2022-07-13

By invitation

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

NCT05481827Age Related Macular Degeneration (AMD)

Gyroscope Therapeutics Limited

Phase 2

225

Barcelona, Madrid, Pamplona

2022-07-12

Active, closed

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

NCT05217446Metastatic Colorectal Cancer

DrugsEncorafenib·Erbitux·Cetuximab·Keytruda

Pfizer

Phase 2

108

Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia, Zaragoza

2022-07-11

Active, closed

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

NCT05360446Coronary Artery Disease

DrugInclisiran sodium

Novartis Pharmaceuticals

Phase 3

610

A Coruña, Barcelona, Córdoba, Madrid, Salamanca, Valencia

2022-07-08

Active, closed

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 3

586

A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Santander, Seville

2022-07-08

Active, closed

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT05379634Myositis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2

Barcelona, Madrid, Santander

2022-07-05

Recruiting

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

NCT05203172Solid Tumors

DrugsVemurafenib·Binimetinib·Encorafenib·Zirabev

Pfizer

Phase 4

210

A Coruña, Badalona, Barcelona, Santander, Lleida, Majadahonda, Madrid, Málaga

2022-07-05

Active, closed

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

NCT05415072Metastatic Uveal Melanoma

Novartis Pharmaceuticals

Phase 1/2

Madrid

2022-07-04

Recruiting

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

NCT04918173Congenital Antithrombin Deficiency

Octapharma

Phase 3

Oviedo, Madrid, Murcia, Ourense

2022-07-01

Active, closed

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 1

160

Barcelona, Madrid, Valencia

2022-06-30

Recruiting

A Natural History Study in Children With a Type II Collagen Disorder With Short Stature

NCT05408715SEDC, Hypochondrogenesis, Semd, Strudwick Type, Kniest Dysplasia

Innoskel

Observational

Madrid

2022-06-29

Active, closed

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

NCT05186753SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis

DrugBezuclastinib

Cogent Biosciences, Inc.

Phase 2

237

Barcelona, Madrid, Toledo

2022-06-27

Active, closed

The Left Bundle Cardiac Resynchronization Therapy Trial

NCT05434962Left Bundle-Branch Block, Heart Failure, Impaired Left Ventricular Function

Óscar Cano Pérez

Not applicable

176

Alicante, L'Hospitalet de Llobregat, Granada, Huelva, Madrid, Majadahonda, Murcia, Valencia

2022-06-27

Active, closed

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997Multiple Myeloma

DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone

Celgene

Phase 3

939

Pamplona, Barcelona, Cáceres, Córdoba, Madrid, Málaga, Murcia, Oviedo

2022-06-23

Active, closed

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

NCT05405166Plasma Cell Myeloma Recurrent

DrugsParacetamol / Acetaminophen·Montelukast·Diphenhydramine·Isatuximab

Sanofi

Phase 3

531

Murcia, Badalona, Santander, Pamplona, Madrid, Salamanca

2022-06-23

Recruiting

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

NCT05462106Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease

AC Immune SA

Phase 1/2

304

Barcelona, Granada, Madrid, Santander, Valencia

2022-06-21

Active, closed

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

NCT05181618Severe Hemophilia A, Moderate Hemophilia A

DrugEmicizumab

Hoffmann-La Roche

Phase 4

136

A Coruña, Barcelona, Madrid, Málaga

2022-06-20

Recruiting

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189Non-Small Cell Lung Cancer

DrugsBNT116·Gotistobart·Cemiplimab·Osimertinib

BioNTech SE

Phase 1

320

Badalona, Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2022-06-17

Active, closed

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

NCT04970901B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma

DrugsLoncastuximab Tesirine·Mosunetuzumab·Polatuzumab Vedotin·Glofitamab

ADC Therapeutics S.A.

Phase 1

154

Barcelona, Madrid, Salamanca, Valencia

2022-06-17

Recruiting

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

NCT05429632Adult Acute Myeloid Leukemia

Priothera SAS

Phase 3

366

Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Salamanca, Valencia

2022-06-16

Active, closed

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

NCT05132075Non-Small Cell Lung Cancer

DrugsOpnurasib·Docetaxel

Novartis Pharmaceuticals

Phase 3

Pamplona, Oviedo, Córdoba, Madrid

2022-06-15

Recruiting

Impact of Endometrial Compaction on Reproductive Outcomes After Cryotransfer of Euploid Embryos in a Natural Cycle

NCT05960370Infertility Due to Nonimplantation

Instituto Bernabeu

Observational

206

Madrid

2022-06-15

Active, closed

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720Non-Hodgkin Lymphoma

DrugsGolcadomide·Epcoritamab·Polatuzumab Vedotin·Doxorubicin Hydrochloride

Genmab

Phase 2

264

Badalona, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia

2022-06-14

Recruiting

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

NCT05433142Clear Cell Renal Cell Carcinoma

Xencor, Inc.

Phase 1

307

Barcelona, Madrid

2022-06-13

Recruiting

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626Locally Advanced Solid Tumor, Metastatic Solid Tumor

DrugsNeladalkib·Repaglinide·Itraconazole·Midazolam

Nuvalent Inc.

Phase 1/2

840

A Coruña, Barcelona, Madrid

2022-06-09

Active, closed

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

NCT05156710Transplant Rejection

DrugsAntithymocyte globulin·Riliprubart·Immunoglobulin·IVIG

Sanofi

Phase 2

Barcelona, Madrid

2022-06-09

Recruiting

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

NCT05280509Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis

DrugsJakavi·Ruxolitinib

Telios Pharma, Inc.

Phase 1/2

Lleida, Madrid, Málaga, Zaragoza

2022-06-09

Active, closed

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

NCT05144256Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

Barcelona, Madrid

2022-06-08

Recruiting

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559Solid Tumor

DrugsNanoparticle Albumin-Bound Paclitaxel·Setidegrasib·Liposomal Irinotecan·Fluorouracil

Astellas Pharma Inc

Phase 1

681

Pamplona, A Coruña, Barcelona, Madrid, Málaga, Seville, Valencia

2022-06-08

Recruiting

Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML

NCT05477589Acute Myeloid Leukemia (AML) in Remission, Stem Cell Transplantation

Vastra Gotaland Region

Phase 3

170

Madrid

2022-06-07

Active, closed

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

NCT05175105Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

Barcelona, Madrid

2022-06-06

Active, closed

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

NCT05115110Spinal Muscular Atrophy (SMA)

DrugsRO7204239·Risdiplam

Hoffmann-La Roche

Phase 2/3

Esplugues de Llobregas, Madrid, Valencia

2022-06-02

Active, closed

AMP SCZ® Observational Study: PREDICT-DPACC

NCT05905003Clinical High Risk, Psychosis, Remission, Conversion

Brigham and Women's Hospital

Observational

2,617

Madrid

2022-06-02

By invitation

Muscular Morphological Ultrasound Epidemiological Study in Dance Professionals

NCT05654168Femoracetabular Impingement

Universidad de Murcia

Observational

Madrid

2022-06-01

Recruiting

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT05211570Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia

DrugVenetoclax

AB Science

Phase 1/2

Alicante, Cáceres, Madrid, Pamplona, Seville

2022-06-01

Recruiting

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

NCT05413421Metastatic Prostate Cancer

DrugsDarolutamide (Nubeqa)·Rinzimetostat·Apalutamide (Erleada)

ORIC Pharmaceuticals

Phase 1

275

Barcelona, Madrid

2022-06-01

Recruiting

Validity and Reliability Study of the Pain Indicator Behavior Scale-Brain Damage (ESCID-DC)

NCT04898491Pain, Brain Injuries, Behavior

Candelas Lopez Lopez

Observational

300

Madrid

2022-06-01

Active, closed

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

NCT05095727Glycogen Storage Disease

ModernaTX, Inc.

Phase 1/2

Madrid, Málaga

2022-06-01

Recruiting

Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry

NCT05673681Melanoma

Fundación Academia Española de Dermatología

Observational

7,000

Badalona, A Coruña, Barcelona, Córdoba, Las Palmas, León, Madrid, Oviedo

2022-06-01

Recruiting

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

NCT05183646FSGS

DrugRepagermanium

Dimerix Bioscience Pty Ltd

Phase 3

286

Almería, Barcelona, Córdoba, Madrid, Majadahonda, Seville

2022-05-30

Recruiting

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

NCT05076175Colitis, Ulcerative

DrugOzanimod

Bristol-Myers Squibb

Phase 2/3

120

Badalona, Esplugues de Llobregat, Madrid

2022-05-30

Active, closed

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

NCT05186974Non-small Cell Lung Cancer

DrugsSacituzumab Govitecan·Paraplatin·Keytruda·Cisplatin

Gilead Sciences

Phase 2

193

A Coruña, Badalona, Barcelona, Madrid, Majadahonda, Pamplona, Rincón de la Victoria, Santiago de Compostela

2022-05-30

Recruiting

A Study of YL201 in Patients With Advanced Solid Tumors

NCT05434234Advanced Solid Tumor

DrugTam-Peli

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2

312

Barcelona, Leganés, Madrid, Moncloa-Aravaca, Pozuelo de Alarcón, Usera, Pamplona, Valencia

2022-05-25

Active, closed

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

NCT05338775Relapsed/ Refractory Multiple Myeloma

DrugsTalquetamab·Teclistamab

Janssen Research & Development, LLC

Phase 1

Badalona, Madrid, Pamplona, Salamanca

2022-05-25

Active, closed

Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System

NCT06157567Skin Laxity, Wrinkle, Skin Condition

Candela Corporation

Not applicable

500

Madrid

2022-05-24

Active, closed

PASS of Paediatric Patients Initiating Selumetinib

NCT05388370Neurofibromatosis Type 1

AstraZeneca

Observational

124

Barcelona, Madrid, Málaga, Santiago de Compostela, Seville

2022-05-23

Recruiting

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml

DrugELVN-001

Enliven Therapeutics

Phase 1

250

Barcelona, Las Palmas de Gran Canaria, Madrid, Toledo, Valencia

2022-05-22

Recruiting

Smartphone-based Ecological Momentary Intervention for Suicide Prevention: a Randomised Clinical Trial

NCT04775160Suicide

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Not applicable

220

Madrid

2022-05-20

Active, closed

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05123703Relapsing-remitting Multiple Sclerosis

DrugsFingolimod·Ocrelizumab

Hoffmann-La Roche

Phase 3

188

Esplugues de Llobregas, Barcelona, Madrid, Seville

2022-05-19

Recruiting

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

NCT05416307Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

DrugELA026

Electra Therapeutics Inc.

Phase 2/3

156

Madrid, Pamplona, Seville, Valencia

2022-05-19

Active, closed

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

NCT05155254Metastatic Melanoma, Unresectable Melanoma

DrugsIO102-IO103·Pembrolizumab

IO Biotech

Phase 3

407

Seville, A Coruña, Barcelona, Madrid, Málaga, Oviedo, Pamplona, Valencia

2022-05-17

Active, closed

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257Limited-Stage Small Cell Lung Cancer

DrugsCarboplatin/cisplatin-etoposide·Serplulimab

Shanghai Henlius Biotech

Phase 3

511

Badajoz, Badalona, Barcelona, Córdoba, Madrid, Seville, Valdecilla, Valencia

2022-05-17

Active, closed

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512Breast Cancer

DrugsEribulin·Dato-DXd·Nab-paclitaxel·Capecitabine

AstraZeneca

Phase 3

644

Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Santiago de Compostela, Seville

2022-05-16

Recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

NCT05039619Lupus Nephritis

DrugsAcetaminophen/paracetamol·Diphenhydramine hydrochloride·Mycophenolate Mofetil·Methylprednisolone

Hoffmann-La Roche

Phase 2

Esplugas de Llobregat, Madrid, Valencia

2022-05-12

Recruiting

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

NCT05307705Breast Cancer

DrugsAnastrozole, Exemestane·Imlunestrant·Abemaciclib·Letrozole

Eli Lilly and Company

Phase 1

260

Barcelona, Madrid, Pozuelo de Alarcón, Valencia

2022-05-11

Active, closed

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

NCT05109728Glioblastoma

Drugs[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Lutathera

Novartis Pharmaceuticals

Phase 1

Granada, Barcelona, Madrid

2022-05-10

Recruiting

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

NCT05090891Fibrodysplasia Ossificans Progressiva (FOP)

Incyte Corporation

Phase 2

Madrid

2022-05-05

Active, closed

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

NCT05280548Fabry Disease

DrugsAgalsidase beta·Replagal·Venglustat·Migalastat HCl

Sanofi

Phase 3

104

Madrid, Alicante, Pontevedra

2022-05-03

Recruiting

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

NCT04879329Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Pembrolizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

372

Sabadell, Barcelona, Madrid, Seville

2022-05-03

Active, closed

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

NCT05296746Breast Cancer Stage II

DrugRibociclib

SOLTI Breast Cancer Research Group

Phase 2

1,100

Palma de Mallorca, Badalona, L'Hospitalet de Llobregat, Barcelona, Granada, León, Madrid, Salamanca

2022-05-03

Active, closed

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

NCT05269004Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 3

1,300

L'Hospitalet de Llobregat, Salt, Santiago de Compostela, Majadahonda, Bilbao, Barcelona, Madrid, Málaga

2022-05-03

Active, closed

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

NCT05270044Melanoma

Pierre Fabre Medicament

Phase 3

815

Badalona, L'Hospitalet de Llobregat, El Palmar, Barcelona, Córdoba, Madrid, Málaga, Valencia

2022-05-02

Recruiting

Heart Rate Regularization in Atrial Fibrilation and Heart Failure

NCT05029570Heart Failure, Atrial Fibrillation

Daniel Rodríguez Muñoz

Not applicable

334

Madrid

2022-04-29

Recruiting

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

NCT05219617Seizures, Lennox Gastaut Syndrome

SK Life Science, Inc.

Phase 3

252

Esplugues de Llobregat, Madrid

2022-04-28

Active, closed

Evolut™ EXPAND TAVR II Pivotal Trial

NCT05149755Moderate Aortic Valve Stenosis

Medtronic Cardiovascular

Not applicable

650

Barcelona, Madrid, Salamanca, Valladolid

2022-04-27

Recruiting

First in Human Study of T3P-Y058-739 (T3P)

NCT05120596Advanced Solid Tumor

DrugPembrolizumab

T3 Pharmaceuticals AG

Phase 1/2

100

Pamplona, Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia

2022-04-26

Active, closed

DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old

NCT04337450HIV Infections

DrugGammora

PENTA Foundation

Phase 2/3

386

Madrid

2022-04-22

Recruiting

Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®

NCT05114850Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Insufficiency, Heart Failure

P+F Products + Features GmbH

Observational

450

Galdakao, Málaga, Barcelona, Córdoba, Lugo, Madrid, Oviedo, Salamanca

2022-04-20

Recruiting

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

NCT04916613Prostate Cancer Metastatic

DrugDarolutamide

UNICANCER

Phase 3

300

Badalona, Barcelona, Girona, Madrid, Manresa, Valencia

2022-04-19

Active, closed

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

NCT05028348Multiple Myeloma

DrugsElotuzumab·Selinexor·Pomalidomide·Dexamethasone

European Myeloma Network B.V.

Phase 3

117

Barcelona, Gijón, Girona, Madrid, Murcia, Pamplona, Salamanca, Santander

2022-04-19

By invitation

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

NCT05303532Cancer

DrugDurvalumab

AstraZeneca

Phase 3

214

Barcelona, Girona, Madrid, Marbella, Santiago de Compostela, Valencia

2022-04-19

Recruiting

Exercise in Adolescents With Cancer

NCT05539794Adolescent Cancer

Universidad Europea de Madrid

Not applicable

136

Villaviciosa de Odón, Madrid

2022-04-15

Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550Non-small Cell Lung Cancer

DrugsAZD0171·Pemetrexed/Cisplatin·Pemetrexed/Carboplatin·Monalizumab

AstraZeneca

Phase 2

630

A Coruña, Alicante, Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Reus

2022-04-14

Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

NCT05208047Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer

DrugsBezuclastinib·Sunitinib·Midazolam

Cogent Biosciences, Inc.

Phase 3

482

Barcelona, El Palmar, Madrid, Santiago de Compostela, Seville, Zaragoza

2022-04-14

Active, closed

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs

DrugsAbiraterone·Abemaciclib·Prednisolone·Prednisone

Eli Lilly and Company

Phase 3

925

Hospitalet, Madrid, Valencia, Badajoz, Seville

2022-04-14

Recruiting

To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

NCT05356741Locally Advanced or Metastatic HER2-Expressing Cancers

DrugsKeytruda·Pembrolizumab

Vir Biotechnology, Inc.

Phase 1/2

645

Madrid, Barcelona, Pamplona, Pozuelo de Alarcón

2022-04-13

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)

DrugBexobrutideg

Nurix Therapeutics, Inc.

Phase 1

572

Barcelona, Gijón, Madrid

2022-04-13

Active, closed

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

NCT05074810Non Small Cell Lung Cancer, KRAS Activating Mutation

DrugLumakras

Verastem, Inc.

Phase 1/2

153

A Coruña, Madrid, Málaga, Seville

2022-04-12

Recruiting

OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.

NCT04493632Pancreatic Neoplasm, Digestive System Neoplasm, Neoplasms by Site, Neoplasms

OncoSil Medical Limited

Observational

500

Las Palmas de Gran Canaria, Madrid, Pamplona, Valladolid

2022-04-12

Active, closed

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

NCT05316155Non-Muscle Invasive Bladder Neoplasms

DrugErdafitinib

Janssen Research & Development, LLC

Phase 1/2

235

Barcelona, Córdoba, Madrid, Valencia

2022-04-11

Active, closed

Exercise Program for Colorectal Older Patients

NCT05448846Colorectal Neoplasms, Aged

Hospital General Universitario Gregorio Marañon

Not applicable

252

Madrid

2022-04-08

By invitation

Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

NCT05248659Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2/3

600

Barcelona, Córdoba, Ellenboro, Madrid, Seville

2022-04-05

Active, closed

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera

NCT05210790Polycythemia Vera

DrugRusfertide

Protagonist Therapeutics, Inc.

Phase 3

293

Barcelona, Madrid, Valencia, Zaragoza

2022-04-01

Recruiting

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

NCT05312879Proteinuric Kidney Disease

Vertex Pharmaceuticals Incorporated

Phase 2/3

466

Barcelona, Córdoba, Madrid, Seville

2022-03-30

Active, closed

To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects

NCT05108259Healthy Volunteers

DrugAdalimumab

Prestige Biopharma Limited

Phase 1

160

Madrid

2022-03-30

Active, closed

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

NCT05270668Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease

DrugTulisokibart

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

154

Barcelona, Madrid, Oviedo, Málaga, Valencia, Zaragoza

2022-03-29

Active, closed

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035Chronic Kidney Disease, Proteinuria

DrugFinerenone

Bayer

Phase 3

219

Esplugues de Llobregat, Barcelona, Madrid, Málaga, Seville

2022-03-28

Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

NCT04895436Chronic Lymphocytic Leukemia (CLL)

DrugsVenclexta·Obinutuzumab·Venetoclax

AbbVie

Phase 2

Madrid

2022-03-28

Active, closed

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

NCT05301842Hepatocellular Carcinoma

DrugsTremelimumab·Lenvatinib·Durvalumab

AstraZeneca

Phase 3

760

Barcelona, Córdoba, Donostia / San Sebastian, Madrid

2022-03-28

Active, closed

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577Prostate Cancer

DrugsCapivasertib·Docetaxel

AstraZeneca

Phase 3

1,035

Barcelona, Córdoba, Lugo, Madrid, Málaga, Sabadell, Seville

2022-03-25

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT04928846Non Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab vedotin·Docetaxel

AbbVie

Phase 3

768

Las Palmas de Gran Canaria, Alcorcón, Fuenlabrada, Ávila, Barcelona, Jaén, Madrid, Valencia

2022-03-25

Active, closed

MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

NCT04769895Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD

MaaT Pharma

Phase 3

Barcelona, El Palmar, Granada, Madrid, Murcia, Pamplona, Salamanca, Santander

2022-03-25

Active, closed

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416Multiple Myeloma

DrugsElranatamab·Lenalidomide

Pfizer

Phase 3

854

Santiago de Compostela, Barcelona, L'Hospitalet Del Llobregat, Terrassa, Badalona, Salamanca, Pozuelo de Alarcón, Madrid

2022-03-25

Active, closed

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

NCT05477576GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors

DrugsRYZ101·Octreotide·Lanreotide·Sunitinib

RayzeBio, Inc.

Phase 3

343

Barcelona, Madrid, Zaragoza

2022-03-24

Active, closed

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

NCT05135559Haemophilia A and B With and Without Inhibitors

DrugConcizumab

Novo Nordisk A/S

Phase 3

153

El Palmar, Barcelona, Madrid, Málaga

2022-03-24

Recruiting

To Evaluate the Safety and Clinical Radiological Outcomes in 2 Years of Embrance Model Reverse Shoulder Arthroplasty

NCT05569161Implantation of a Reverse Shoulder Prosthesis

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Observational

250

Madrid

2022-03-24

Active, closed

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

NCT05224141Small Cell Lung Carcinoma

DrugsPembrolizumab/Vibostolimab·Tecentriq·Paraplatin·Etoposide

Merck Sharp & Dohme LLC

Phase 3

460

Madrid, Málaga, Barcelona, Seville

2022-03-24

Active, closed

Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation

NCT05269862Parkinson Disease

Abbott Medical Devices

Not applicable

100

Badalona, Madrid, Seville

2022-03-24

Active, closed

Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used as a Bridging Stent With Branched and Fenestrated Endografts in the Treatment of Aortic Aneurysms Involving the Renal-Mesenteric Arteries

NCT05143138Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm

W.L.Gore & Associates

Observational

259

Granada, Madrid

2022-03-23

Active, closed

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

NCT04980222Lymphoma

DrugsGlofitamab·Tocilizumab·Vincristine·Doxorubicin

Hoffmann-La Roche

Phase 2

Barcelona, Madrid, Salamanca

2022-03-22

Active, closed

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

NCT05277051Neoplasms

DrugsRemzistotug·GSK5764227·Nelistotug·Belrestotug

GlaxoSmithKline

Phase 1

152

Barcelona, Madrid, Málaga

2022-03-22

Recruiting

Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis

NCT04804553Active Juvenile Psoriatic Arthritis

DrugApremilast

Amgen

Phase 3

San Cristóbal de La Laguna, Barcelona, Esplugues de Llobregat, Valencia, Madrid

2022-03-17

Active, closed

COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events

NCT05333068Multivessel Coronary Artery Disease, Ischemia, Vulnerable Plaque, Coronary Artery Disease

Diagram B.V.

Not applicable

1,223

Barcelona, Madrid, Santander, Valencia

2022-03-16

Active, closed

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728Carcinoma, Renal Cell

DrugsBelzutifan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,800

Girona, Madrid, Valencia, Barcelona, Lugo, Málaga

2022-03-15

Active, closed

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

530

A Coruña, Barakaldo, Barcelona, Bilbao, Córdoba, Ferrol, Madrid, Santander

2022-03-15

Active, closed

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

NCT05262400Breast Cancer, Solid Tumors

DrugsPF-07104091·Atirmociclib

Pfizer

Phase 1/2

235

Barcelona, Madrid, Seville

2022-03-14

Active, closed

Parenteral Antiplatelet Agents in Real-world Spanish PCI Patients

NCT05193019Ischemic Heart Disease, Acute Coronary Syndrome

Fundación EPIC

Observational

717

L'Hospitalet de Llobregat, Barakaldo, Galdakao, Gijón, León, Madrid, Pamplona, Salamanca

2022-03-14

Recruiting

Anatomy-based Fitting in Cochear Implant Users

NCT05360212Cochlear Implant, Outcomes, Quality of Life

Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz

Not applicable

Madrid

2022-03-11

Active, closed

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

DrugsRuxience·Truxima·Zanubrutinib·Obinutuzumab

BeOne Medicines

Phase 3

799

Badalona, Burgos, Cadiz, Granada, L'Hospitalet de Llobregat, León, Madrid, Majadahonda

2022-03-10

Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

NCT05315700Solid Tumors

ORIC Pharmaceuticals

Phase 1/2

350

Barcelona, Madrid

2022-03-10

Active, closed

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT05238883Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma

DrugTislelizumab

HiFiBiO Therapeutics

Phase 1

Barcelona, Madrid, Valencia

2022-03-10

Active, closed

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

NCT05280470Extensive-stage Small-cell Lung Cancer

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 2

187

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville

2022-03-09

Active, closed

Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)

NCT06282432Leukocyte Adhesion Deficiency

Rocket Pharmaceuticals Inc.

Observational

Madrid

2022-03-09

Recruiting

An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

NCT05295433Methylmalonic Acidemia

ModernaTX, Inc.

Phase 1/2

Barakaldo, Madrid

2022-03-08

Active, closed

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures

DrugFintepla

Zogenix, Inc.

Phase 3

Barcelona, Madrid, Santiago de Compostela

2022-03-08

Active, closed

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

NCT05132582HER2 Positive Breast Cancer

DrugsPerjeta·Tucatinib·Herceptin·Pertuzumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

654

Málaga, Palma de Mallorca, EI Palmar, Barcelona, Cáceres, Madrid, Valencia, La Laguna Tenerife

2022-03-07

Active, closed

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

NCT05215340Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

740

Barcelona, Lleida, Madrid, Málaga, Ourense, Seville, Valencia, Zaragoza

2022-03-04

Active, closed

Radial Ablation for the Control of Persistent Atrial Fibrillation

NCT04662489Persistent Atrial Fibrillation

Fundacion para la Innovacion en Biomedicina (FIBMED)

Not applicable

244

Madrid, Majadahonda

2022-03-01

Active, closed

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT05243550Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder

UroGen Pharma Ltd.

Phase 3

240

Barcelona, Bilbao, Madrid

2022-03-01

Active, closed

A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

NCT05250973Amyloidosis

DrugsBortezomib·Daratumumab·Dexamethasone·Cyclophosphamide

Janssen Research & Development, LLC

Phase 2

151

Badalona, Barcelona, Madrid, Pamplona, Salamanca

2022-03-01

Recruiting

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

NCT05156398Migraine

DrugRimegepant

Pfizer

Phase 3

640

Sabadell, Valladolid, Vigo, Valencia, Madrid, Seville

2022-02-28

Recruiting

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes

DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax

Sumitomo Pharma America, Inc.

Phase 1/2

606

Albacete, Barcelona, Cáceres, Las Palmas, Madrid, Oviedo, Salamanca, Santander

2022-02-28

Active, closed

Atropine and Spectacle Combination Treatment (ASPECT): 12-month Results of a Randomized Clinical Trial for Myopia Control

NCT06431841Myopia

DrugAtropine

Hospital San Carlos, Madrid

Phase 4

111

Madrid

2022-02-23

Active, closed

Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)

NCT05051033Mitral Valve Regurgitation

Annetine Gelijns

Not applicable

450

Palma de Mallorca, Vigo, Barcelona, Madrid, Oviedo

2022-02-21

Recruiting

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05128825High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

DrugAzenosertib

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 2

310

Barcelona, Madrid, Murcia, Valencia

2022-02-17

Active, closed

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

NCT05121376Hereditary Angioedema, HAE

BioMarin Pharmaceutical

Phase 1/2

Barcelona, Madrid

2022-02-15

Active, closed

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

NCT05204927Metastasis From Malignant Tumor of Prostate

DrugEnzalutamide

Curium US LLC

Phase 3

439

Madrid, Málaga, Salamanca

2022-02-14

Recruiting

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

NCT04779320Crohn's Disease (CD)

DrugVedolizumab

Takeda

Phase 3

120

Esplugues de Llobregat, Sagunto, Madrid, Málaga, Seville

2022-02-10

Recruiting

Analysis of Musical and Voice Skills in Children and Adult Cochlear Implant Users

NCT05319678Cochlear Implant, Music, Voice

Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz

Observational

Madrid

2022-02-10

Active, closed

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

NCT05202509Atherosclerotic Cardiovascular Disease

DrugObicetrapib

NewAmsterdam Pharma

Phase 3

9,541

A Coruña, Alicante, Almería, Barcelona, Córdoba, Granada, Madrid, Málaga

2022-02-07

Active, closed

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840Non-Small Cell Lung Cancer

DrugsMonalizumab·Oleclumab·Durvalumab

AstraZeneca

Phase 3

1,051

Barcelona, Granada, Madrid, Santiago de Compostela, Valencia

2022-02-07

Active, closed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987Endometrial Neoplasms

DrugsTaxotere·Paraplatin·Taxol·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

280

L'Hospitalet de Llobregat, A Coruña, Madrid, Pamplona, Valencia, Barcelona, Seville

2022-02-03

By invitation

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05076617Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

300

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Seville, Terrassa, Valencia, Valladolid

2022-02-03

Active, closed

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

NCT05063162Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)

DrugRozanolixizumab

UCB Biopharma SRL

Phase 3

113

Barcelona, Madrid, Málaga, Murcia, Seville

2022-02-02

Recruiting

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

NCT05183984Ovarian Cancer

DrugsBevacizumab-awwb·Niraparib

ARCAGY/ GINECO GROUP

Phase 2

390

A Coruña, Barcelona, Cáceres, El Palmar, Murcia, Jerez de la Frontera, Madrid, Málaga, Oviedo

2022-02-01

By invitation

Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102

NCT07527975Fanconi Anemia

DrugRP-L102

Rocket Pharmaceuticals Inc.

Observational

Madrid

2022-02-01

Active, closed

Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

NCT04980833PIK3CA-related Overgrowth Spectrum (PROS)

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2

Madrid

2022-01-27

Recruiting

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

NCT05098132Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC

DrugsPembrolizumab KEYTRUDA·Pemetrexed·Carboplatin

Synthekine

Phase 1/2

364

Barcelona, Logroño, Madrid, Málaga, Pamplona

2022-01-25

Active, closed

Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

NCT05234190Rejection; Transplant, Liver, Liver Failure, Liver Diseases

Quell Therapeutics Limited

Phase 1/2

Barcelona, Córdoba, Madrid

2022-01-21

Active, closed

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

NCT05309668Neurofibromatosis Type 1

DrugSelumetinib

AstraZeneca

Phase 1/2

Barcelona, Madrid

2022-01-21

Active, closed

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT05197049Crohn Disease

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3

Janssen Research & Development, LLC

Phase 3

350

Gijón, Huelva, Madrid, Seville, Vigo, Villajoyosa

2022-01-19

Recruiting

REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs

NCT05223413Anthracycline-induced Cardiac Toxicity, Lymphoma

Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Not applicable

608

Alcalá de Henares, Barcelona, Granada, Madrid, Salamanca, Seville, Valladolid

2022-01-18

Active, closed

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

DrugsEvorpacept·Ramucirumab·Herceptin·Taxol

ALX Oncology Inc.

Phase 2/3

127

Alicante, Badalona, Barcelona, Córdoba, Lugo, Madrid, Santander, Zaragoza

2022-01-15

Active, closed

Screening for High Frequency Malignant Disease

NCT05117840Lung Cancer

Guardant Health, Inc.

Observational

12,000

Benalmádena, Valladolid, Mataró, Boadilla del Monte, Madrid, Móstoles

2022-01-13

Active, closed

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD

DrugsEylea·Aflibercept

AbbVie

Phase 3

735

Santiago de Compostela, L'Hospitalet de Llobregat, Córdoba, Las Palmas de Gran Canaria, Majadahonda, Barcelona, Madrid

2022-01-13

Recruiting

The "Global Paradise System" Registry

NCT05027685Hypertension

ReCor Medical, Inc.

Observational

3,000

Barcelona, Madrid

2022-01-13

Active, closed

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

NCT05081609Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer

DrugsTrastuzumab emtansine·Trastuzumab·Pembrolizumab

Ascendis Pharma Oncology Division A/S

Phase 1/2

320

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, Oviedo, Pamplona, Seville

2022-01-11

Active, closed

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

NCT05217628Trigeminal Neuralgia

Noema Pharma AG

Phase 2/3

166

Madrid, Seville, Valencia

2022-01-11

Recruiting

Incidence of Peri-implant Mucositis in Patients With Treated Periodontitis

NCT05356806Peri-implant Mucositis

Universidad Complutense de Madrid

Observational

277

Madrid

2022-01-10

Active, closed

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

NCT05067634Partial Epilepsy

SK Life Science, Inc.

Phase 3

140

Barcelona, Madrid, Seville

2022-01-10

Active, closed

Community-Based Exercise Oncology: Real-World Evidence of High Adherence, Improved Quality of Life and Cost-Effectiveness Across the Cancer Continuum

NCT07368192Cancer, Neoplams

University of Castilla-La Mancha

Observational

492

Madrid

2022-01-10

Recruiting

International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors

NCT05363657Kidney Cancer

Azienda Ospedaliero-Universitaria Careggi

Observational

10,000

Barcelona, Madrid

2022-01-10

Active, closed

A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

NCT05071300Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

DrugEplontersen

Ionis Pharmaceuticals, Inc.

Phase 3

151

Madrid, Palma de Mallorca

2022-01-04

Recruiting

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

NCT05118789Locally Advanced Solid Tumor, Metastatic Solid Tumor

Nuvalent Inc.

Phase 1/2

359

A Coruña, Barcelona, Madrid

2022-01-04

Active, closed

Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II-III

NCT07821333Colorectal Neoplasms Malignant, Minimal Residual Disease, Circulating Tumor Cell

DrugsFolfoxiri·Folfox

Fundación para la Investigación del Hospital Clínico de Valencia

Phase 2

L'Hospitalet de Llobregat, Barcelona, Córdoba, Madrid, Valencia

2022-01-01

Recruiting

ENDOBARC-S Study: "Endovascular Branched Stent-grafts for Aortic ARCh Pathologies in Spain"

NCT05309707Thoracic Aortic Aneurysm, Thoracic Aortic Dissection, Stent-Graft Endoleak, Stent-Graft Stenosis

Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery

Observational

100

Madrid

2022-01-01

Active, closed

Assessment of Reproductive Outcomes in Non-Male Factor Infertility Patients: Conventional in Vitro Fertilisation Versus Intracytoplasmic Sperm Injection

NCT06670586In Vitro Fertilization, Infertility Assisted Reproductive Technology

Maria Dolores Cuquerella Fernandez-Vazquez

Not applicable

128

Madrid

2022-01-01

Active, closed

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

NCT05139602Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 2

210

Manises, Barcelona, Granada, Madrid

2021-12-28

Active, closed

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

NCT04919226Neuroendocrine Tumors

DrugsFOLFOX (Folinic acid·Everolimus·Fluorouracil·Oxaliplatin

ITM Solucin GmbH

Phase 3

259

Barcelona, Madrid, Oviedo, Santiago de Compostela, Valencia

2021-12-21

Active, closed

Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer

NCT04905069Prostate Cancer

Boston Scientific Corporation

Not applicable

500

Barakaldo, Madrid

2021-12-21

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

NCT04770753Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

194

Barcelona, Madrid, Murcia, Seville

2021-12-20

Active, closed

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

NCT05060627Relapsed Multiple Myeloma

DrugsBelantamab mafodotin·Carfilzomib·Dexamethasone

PETHEMA Foundation

Phase 1/2

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Oviedo, Palma de Mallorca, Pamplona

2021-12-20

Active, closed

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

NCT05038735Breast Cancer

DrugsAlpelisib·Fulvestrant

Novartis Pharmaceuticals

Phase 3

210

Badajoz, Pozuelo de Alarcón, Oviedo, A Coruña, Barcelona, Madrid, Málaga, Zaragoza

2021-12-17

Recruiting

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

NCT05067283Advanced Solid Tumors

DrugsCalderasib·Leucovorin·Cetuximab·Adrucil

Merck Sharp & Dohme LLC

Phase 1

830

Madrid, Barcelona

2021-12-17

Recruiting

Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer

NCT06892860Urinary Bladder Neoplasms

DrugAvelumab

Queen Mary University of London

Phase 2

320

Madrid

2021-12-16

Recruiting

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

NCT05037760Myelofibrosis

DrugsElritercept·Ruxolitinib

Takeda

Phase 2

135

Badalona, Barcelona, Madrid, Salamanca, Valencia, Zaragoza

2021-12-16

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

NCT04953897Acute Myeloid Leukemia, Myelodysplastic Syndromes

DrugDecitabine

Taiho Oncology, Inc.

Phase 1

Barcelona, La Rioja, Lleida, Madrid, Murcia, Valencia

2021-12-15

Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor

DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab

Exelixis

Phase 1

1,394

Badajoz, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander, Seville, Valencia

2021-12-14

Active, closed

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

NCT04954859Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

360

HebrOn, León, Madrid, Santander, Valencia, Vigo

2021-12-14

Recruiting

Pathological Response After Neoadjuvant Treatment on NSCLC

NCT05167487Stage IIIA Non-small Cell Lung Cancer

DrugsParaplatin·Cisplatin·Carboplatin

Fundación GECP

Observational

150

A Coruña, Alicante, Badalona, Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda

2021-12-13

Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173Carcinoma, Squamous Cell

DrugsJNJ-90301900·Erbitux·Cetuximab

Johnson & Johnson Enterprise Innovation Inc.

Phase 3

500

Barakaldo, Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Pamplona

2021-12-10

Active, closed

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

NCT04999969Locally Advanced or Metastatic Solid Tumours

DrugsAZD0171·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 2

126

Badalona, Barcelona, Madrid, Majadahonda, Pamplona

2021-12-10

Active, closed

EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke

NCT05029414Acute Ischemic Stroke

University Hospital, Basel, Switzerland

Not applicable

543

Barcelona, Girona, Madrid, Murcia, Valladolid

2021-12-09

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer

DrugsRLY-2608·Atirmociclib·Ribociclib·Palbociclib

Relay Therapeutics, Inc.

Phase 1

930

Barcelona, Valencia, Madrid

2021-12-08

Recruiting

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

350

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Seville, Terrassa, Valencia, Valladolid

2021-12-07

Active, closed

Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

NCT05002777Warm Autoimmune Hemolytic Anemia (wAIHA)

DrugRilzabrutinib

Sanofi

Phase 2

Barakaldo, Barcelona, Madrid, Seville

2021-12-07

By invitation

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

NCT05145010Achondroplasia

DrugInfigratinib

QED Therapeutics, a BridgeBio company

Phase 2

300

Madrid, Málaga, Vitoria-Gasteiz

2021-12-06

Active, closed

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZanidatamab·Herceptin·Trastuzumab·Adrucil

Jazz Pharmaceuticals

Phase 3

920

Sabadell, Pamplona, Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Málaga

2021-12-02

Recruiting

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

NCT05164172Migraine

DrugEptinezumab

H. Lundbeck A/S

Phase 3

600

Vigo, Barcelona, Madrid, Seville, Valencia

2021-12-01

Active, closed

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

NCT05060016Relapsed/Refractory Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 2

222

Málaga, Barcelona, L'Hospitalet de Llobregat, Majadahonda, Valencia, Madrid

2021-12-01

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

NCT04770779Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

258

Barcelona, Madrid, Murcia, Seville

2021-11-30

Recruiting

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT04910685Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis

Blueprint Medicines Corporation

Phase 2/3

534

Barcelona, Madrid, Toledo

2021-11-30

Active, closed

PREvention of Intrauterine Adhesion After Adhesiolysis With Novel Tri-block deGradable Polymer Film.

NCT04963179Asherman Syndrome, Intrauterine Adhesion

Womed

Not applicable

160

Barcelona, Madrid

2021-11-29

Recruiting

Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor

NCT05146440Advanced Soft-tissue Sarcoma, Advanced L-sarcomas, Other Advanced Sarcomas, Advanced Solid Tumor

Grupo Espanol de Investigacion en Sarcomas

Phase 1/2

195

Zaragoza, Barcelona, Madrid

2021-11-23

Recruiting

HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

NCT04743765Hip Fractures, Myocardial Injury

Population Health Research Institute

Not applicable

1,100

Barcelona, Sabadell, Sant Pere de Ribes, Terrassa, Marbella, Valladolid, Madrid

2021-11-22

Active, closed

Registry for Patients Undergoing Penile Prosthesis Implantation for Male Erectile Dysfunction

NCT03849586Erectile Dysfunction

European Association of Urology Research Foundation

Observational

1,076

Barcelona, Boadilla del Monte, Madrid, Majadahonda, Móstoles, Palma de Mallorca, Santander

2021-11-19

Active, closed

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

NCT04924608Neurofibromatosis 1, Plexiform Neurofibroma (PN)

DrugSelumetinib

AstraZeneca

Phase 3

145

Badalona, Madrid

2021-11-19

Active, closed

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

NCT05130450Familial Chylomicronemia Syndrome

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

Barcelona, Madrid, Seville

2021-11-18

Active, closed

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

NCT05091567Small-Cell Lung Cancer

DrugsLurbinectedin·Tecentriq·Etoposide·Atezolizumab

Hoffmann-La Roche

Phase 3

660

A Coruña, Barcelona, Madrid, Málaga, Seville

2021-11-18

Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05160584Relapsed/Refractory Multiple Myeloma

Janssen Pharmaceutica N.V., Belgium

Observational

300

Barcelona, Gijón, Granada, Jerez de la Frontera, León, Madrid, Palma, Pamplona

2021-11-18

Active, closed

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05089734Non-Small Cell Lung Cancer

DrugsSacituzumab Govitecan·Docetaxel

Gilead Sciences

Phase 3

603

A Coruña, Badalona, Barakaldo, Barcelona, Cáceres, Girona, Madrid, Málaga

2021-11-17

Recruiting

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

NCT05145127Hemophilia A, Hemophilia B

DrugMarstacimab

Pfizer

Phase 3

245

A Coruña, Barcelona, Madrid, Zaragoza

2021-11-17

Active, closed

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

NCT04988295Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

776

A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Pamplona, Seville

2021-11-17

Active, closed

Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels - TRANSFORM II

NCT04893291Coronary Artery Disease, Coronary Artery Stenosis

Fondazione Ricerca e Innovazione Cardiovascolare ETS

Not applicable

1,820

Ciudad Real, Lugo, Madrid, Santander, Valencia, Vigo, Vitoria-Gasteiz

2021-11-16

Active, closed

Clinical Trial With Artiflex Presbyopic (Artiplus)

NCT04632784Presbyopia, Ametropia, Refractive Errors, Myopia

Ophtec BV

Not applicable

Bilbao, Barcelona, Madrid, Seville

2021-11-12

Active, closed

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

NCT05039840Systemic Lupus Erythematosus

DrugFrexalimab

Sanofi

Phase 2

109

Sabadell, Madrid, Valencia, Valladolid

2021-11-10

Recruiting

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

NCT05130437Propionic Acidemia

DrugMRNA-3927

ModernaTX, Inc.

Phase 1/2

Barakaldo, Madrid

2021-11-09

Recruiting

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

NCT04996875Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)

DrugBezuclastinib

Cogent Biosciences, Inc.

Phase 2

140

Barcelona, Madrid

2021-11-09

Active, closed

Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

NCT05112237Cardiomyopathy

Tenaya Therapeutics

Observational

200

Barcelona, Madrid, Vigo

2021-11-01

Active, closed

A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05117476Advanced Solid Tumor, NSCLC

DrugsCLN-619·Carboplatin (AUC 6)·Dato-DXd·Pemetrexed

Cullinan Therapeutics Inc.

Phase 1

440

Las Palmas de Gran Canaria, Barcelona, Madrid, Pamplona, Sabadell

2021-10-29

Active, closed

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

NCT05043090Papillary Renal Cell Carcinoma

DrugsSavolitinib·Sunitinib·Durvalumab

AstraZeneca

Phase 3

148

A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pamplona, Seville

2021-10-28

Active, closed

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin

AstraZeneca

Phase 3

454

L'Hospitalet de Llobregat, Madrid, Málaga, Valencia

2021-10-28

Active, closed

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

NCT04712097Relapsed or Refractory Follicular Lymphoma

DrugsMosunetuzumab·Lenalidomide·Rituximab

Hoffmann-La Roche

Phase 3

478

Guipuzcoa, Madrid, Murcia, Seville, Valencia

2021-10-27

Active, closed

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

NCT04988386Amyloid Cardiomyopathy, Transthyretin-Related

DrugAcoramidis

Eidos Therapeutics, a BridgeBio company

Phase 3

389

Palma de Mallorca, Santiago de Compostela, Madrid, Majadahonda, Pamplona, Valencia

2021-10-27

Active, closed

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

NCT05181592Myelodysplastic Syndromes

DrugsReblozyl·Luspatercept

GWT-TUD GmbH

Phase 3

Badalona, Barcelona, Madrid, Oviedo, Salamanca, Valencia

2021-10-27

Active, closed

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

NCT04963296Systemic Lupus Erythematosus

DrugsAcetaminophen/paracetamol·Diphenhydramine hydrochloride·Methylprednisolone·Obinutuzumab

Hoffmann-La Roche

Phase 3

303

Barcelona, Madrid

2021-10-26

Active, closed

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer

DrugsHerzuma·Perjeta·Herceptin·Adriamycin

AstraZeneca

Phase 3

927

Barcelona, Madrid, Seville, Vigo

2021-10-25

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

400

L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia

2021-10-25

Recruiting

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT04929223Metastatic Colorectal Cancer

DrugsDivarasib·Tiragolumab·Inavolisib·Tecentriq

Hoffmann-La Roche

Phase 1

542

Donostia / San Sebastian, Majadahonda, Barcelona, Madrid, Valencia, Zaragoza

2021-10-22

Active, closed

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

NCT05050942Gastro-enteropancreatic Neuroendocrine Tumor

DrugsCAM2029·Octreotide LAR

Camurus AB

Phase 3

332

A Coruña, Barcelona, Elche, Girona, Madrid, Málaga, Murcia, Oviedo

2021-10-22

Active, closed

Healthy Communities: A Healthy City Preventive Program on Cardiovascular Health and Well-being (HC)

NCT05974826Heart Disease Risk Factors, Healthy Lifestyle, Health Behavior

Foundation for Science, Health and Education, Spain

Not applicable

2,000

Madrid

2021-10-20

Active, closed

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

NCT04958239Neoplasms

DrugsEzabenlimab·Pembrolizumab

Boehringer Ingelheim

Phase 1

151

Badalona, Barcelona, Madrid, Pamplona

2021-10-18

Active, closed

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866Breast Cancer

DrugsEribulin·Dato-DXd·Vinorelbine·Capecitabine

AstraZeneca

Phase 3

732

A Coruña, Barcelona, Bilbao (Vizcaya), Huelva, L'Hospitalet de Llobregat, Madrid, Málaga, Seville

2021-10-18

Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer

DrugsPalacaparib·Saruparib·Rilvegostomig

AstraZeneca

Phase 1/2

460

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2021-10-18

Active, closed

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169Multiple Myeloma

DrugsTeclistamab·Pomalidomide·Bortezomib·Daratumumab

Janssen Research & Development, LLC

Phase 3

587

Barcelona, Gijón, Las Palmas de Gran Canaria, Madrid, Palma, Pamplona, Pozuelo de Alarcón, Salamanca

2021-10-14

Active, closed

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

NCT05059262Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse

DrugVimseltinib

Deciphera Pharmaceuticals, LLC

Phase 3

123

Barcelona, Madrid

2021-10-14

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 1

520

Santiago de Compostela, Badalona, Alcorcón, Pamplona, Barcelona, Jaén, Madrid, Seville

2021-10-13

Active, closed

Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

NCT04884282Metastatic Non Small Cell Lung Cancer

DrugsTedopi·Docetaxel·Nivolumab

Fondazione Ricerca Traslazionale

Phase 2

105

A Coruña, Barcelona, Madrid, Mataró, Málaga

2021-10-12

Active, closed

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT04895696Systemic Lupus Erythematosus

Beeline Medicines Corporation

Phase 2

248

Santander, A Coruña, Barcelona, Madrid, Seville

2021-10-11

Recruiting

Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling

NCT04936620Spinal Cord Injuries

St George's, University of London

Not applicable

222

Madrid

2021-10-08

Active, closed

Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia

NCT05011123Yellow Fever

DrugYellow fever vaccine

Sanofi Pasteur, a Sanofi Company

Phase 2

690

Barcelona, L'Hospitalet de Llobregat, Madrid

2021-10-07

Active, closed

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

NCT04931342Ovarian Cancer

DrugsCobimetinib·Ipatasertib·Giredestrant·Inavolisib

Hoffmann-La Roche

Phase 2

176

Barcelona, Madrid, Málaga

2021-10-07

Recruiting

MYTHS - MYocarditis THerapy With Steroids

NCT05150704Myocarditis Acute

DrugMethylprednisolone

Niguarda Hospital

Phase 3

288

A Coruña, Barcelona, Madrid, Málaga, Murcia

2021-10-07

Active, closed

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

DrugsBosutinib·Asciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

405

Granada, El Palmar, Pamplona, Barcelona, Madrid

2021-10-06

Active, closed

Study of Lacutamab in Peripheral T-cell Lymphoma

NCT04984837Peripheral T Cell Lymphoma, Relapse/Recurrence

DrugsOxaliplatine·Gemcitabine

The Lymphoma Academic Research Organisation

Phase 2

Barcelona, Madrid, Santander, Valencia

2021-10-05

Active, closed

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308Breast Neoplasms, Neoplasm Metastasis

DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

874

Barcelona, Cáceres, Lleida, Madrid, San Cristóbal de La Laguna, Valencia, Granada, Seville

2021-10-04

Active, closed

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

NCT04603807Carcinoma, Non-Small-Cell Lung

DrugsEntrectinib·Crizotinib

Hoffmann-La Roche

Phase 3

217

A Coruña, Barcelona, Madrid, Málaga

2021-09-30

Active, closed

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

NCT05059522Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer

DrugsCMP 001·Utomilumab·Talazoparib·Axitinib

Pfizer

Phase 3

Barcelona, L'Hospitalet de Llobregat, Madrid, Seville

2021-09-29

Active, closed

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer

DrugSabestomig

AstraZeneca

Phase 1/2

136

Barcelona, Madrid

2021-09-28

Active, closed

Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075Conventional Chondrosarcoma

DrugINBRX-109

Inhibrx Biosciences, Inc

Phase 2

206

Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2021-09-23

Active, closed

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

282

Madrid, Oviedo, Barcelona, Seville

2021-09-23

Active, closed

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136Primary Biliary Cholangitis, PBC

DrugVolixibat

Mirum Pharmaceuticals, Inc.

Phase 2

333

Barcelona, Madrid, Seville, Zaragoza

2021-09-22

Active, closed

A Non-interventional Cohort Safety Study of Patients With hATTR-PN

NCT04850105Hereditary Transthyretin Amyloidosis With Polyneuropthy

Akcea Therapeutics

Observational

202

Huelva, Oviedo, Palma de Mallorca, Villarreal, Barcelona, Madrid

2021-09-21

Active, closed

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

600

Barcelona, Madrid, Majadahonda, Marbella, Oviedo, Pozuelo de Alarcón, Seville, Toledo

2021-09-20

Active, closed

Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients

NCT04888312Metastatic Pancreatic Ductal Adenocarcinoma

DrugMitazalimab

Alligator Bioscience AB

Phase 1/2

Barcelona, Madrid, Seville, Zaragoza

2021-09-17

Active, closed

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

NCT04776252HIV-1 Infection

DrugDOR/ISL

Merck Sharp & Dohme LLC

Phase 3

2,000

Elche, Badalona, Barcelona, Madrid

2021-09-15

Active, closed

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

NCT04909801Rheumatoid Arthritis

DrugsAbatacept·Humira·Adalimumab·Methotrexate

Bristol-Myers Squibb

Phase 3

338

A Coruña, Madrid, Santander

2021-09-15

Active, closed

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

NCT04774718ALK Fusion-positive Solid or CNS Tumors

DrugAlectinib

Hoffmann-La Roche

Phase 1/2

Madrid, Seville, Valencia

2021-09-14

Active, closed

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

NCT04995523Non-Small-Cell Lung Carcinoma

DrugRilvegostomig

AstraZeneca

Phase 1/2

212

Barcelona, Madrid

2021-09-14

Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma

DrugTacabrutideg

BeOne Medicines

Phase 1/2

689

Barcelona, Madrid, Majadahonda, Valencia

2021-09-13

Active, closed

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT04765059Non-small Cell Lung Cancer

DrugCarboplatin

AstraZeneca

Phase 3

Alicante, Barcelona, Córdoba, León, Madrid, Málaga, Murcia, Oviedo

2021-09-12

Recruiting

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT04704323Lymphocytic Leukemia, Chronic, SLL

Catapult Therapeutics

Phase 1

Madrid, Santander

2021-09-10

Recruiting

Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease

NCT04528082Behçet Disease

DrugApremilast

Amgen

Phase 3

Seville, Barcelona, Esplugues de Llobregat, Valencia, Madrid

2021-09-09

Recruiting

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer

Guardant Health, Inc.

Observational

2,285

A Coruña, Barcelona, Girona, Las Palmas de Gran Canaria, Madrid, Málaga, Sabadell, Santiago de Compostela

2021-09-07

Active, closed

Diagnostic and Clinical Management of Non-Obstructive Myocardial Ischemia in Patients With Long Covid-19 Syndrome and New Onset Chest Pain

NCT07559994Angina (Stable), INOCA (Ischemia With Non Obstructive Coronary Artery Disease), Long COVID-19 Syndrome

Fundacion Investigacion Interhospitalaria Cardiovascular

Not applicable

108

Madrid

2021-09-02

Active, closed

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811Non Small Cell Lung Cancer

DrugTaletrectinib

Nuvation Bio Inc.

Phase 2

217

Barcelona, Madrid, Málaga, Seville, Valencia

2021-09-01

Recruiting

Patient Reported Outcomes Following Cancer of the Rectum

NCT04936581Sphincter Ani Incontinence, Rectal Cancer

University Hospital Gregorio Marañón

Observational

200

Madrid

2021-09-01

Active, closed

A Study of AL102 in Patients With Progressing Desmoid Tumors

NCT04871282Desmoid, Desmoid Tumor

Immunome, Inc.

Phase 2/3

198

Barcelona, Madrid, Zaragoza

2021-09-01

Active, closed

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

NCT04929210Arthritis, Psoriatic

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 4

411

A Coruña, Barakaldo, Barcelona, Bilbao, Córdoba, Madrid, Málaga, Sabadell

2021-08-30

Recruiting

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer

DrugsKeytruda·Pembrolizumab

Medicenna Therapeutics, Inc.

Phase 1/2

115

Badalona, Barcelona, Madrid, Oviedo, Torrejón

2021-08-27

Active, closed

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

NCT05049798Arthritis, Psoriatic

DrugsIL-17i·Tremfya·Guselkumab

Janssen Pharmaceutica N.V., Belgium

Observational

1,314

A Coruña, Algeciras / Cadiz, Barcelona, Bilbao, Córdoba, Granada, Madrid, Oviedo

2021-08-25

Active, closed

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

NCT04994795Non-small Cell Lung Cancer Metastatic

Sophia Genetics SAS

Observational

4,000

Madrid, Valencia

2021-08-21

Active, closed

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728NASH - Nonalcoholic Steatohepatitis

Inventiva Pharma

Phase 3

1,000

Almería, Badalona, Palma de Mallorca, Barcelona, Sabadell, León, Madrid, Majadahonda

2021-08-19

Active, closed

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893Multiple Myeloma

DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine

Janssen Research & Development, LLC

Phase 3

743

Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Salamanca, Santander, Seville

2021-08-19

Active, closed

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

NCT05007782Advanced Solid Tumor

DrugsDenikitug·Zimberelimab

Gilead Sciences

Phase 1

304

Barcelona, Madrid, Pamplona

2021-08-18

Recruiting

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

NCT04844866Diffuse Large B-cell Lymphoma

Miltenyi Biomedicine GmbH

Phase 2

213

Barcelona, Madrid, Murcia, Pamplona, Salamanca

2021-08-18

Active, closed

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

NCT04976634Neoplasm Malignant

DrugsBelzutifan·Lenvatinib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

730

Badalona, Santiago de Compostela, Madrid, Oviedo, Barcelona

2021-08-18

Recruiting

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

NCT04629833Steroid-refractory Acute Graft-versus-host Disease

DrugMC0518

medac GmbH

Phase 3

210

Badalona, Barcelona, Madrid, Málaga, Valencia

2021-08-16

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor

DrugBelzutifan

Merck Sharp & Dohme LLC

Phase 2

355

Madrid, Oviedo, Barcelona

2021-08-12

Recruiting

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT05003986Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis

DrugSparsentan

Travere Therapeutics, Inc.

Phase 2

Barcelona, Madrid, Seville

2021-08-12

Active, closed

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

NCT04674683Unresectable or Metastatic Melanoma, Progressive Brain Metastasis

DrugsChidamide·Nivolumab

HUYABIO International, LLC.

Phase 3

450

Barcelona, Madrid, Málaga, Seville, Zaragoza

2021-08-12

Active, closed

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

NCT05005975EPP, XLP

Tanabe Pharma America, Inc.

Phase 3

286

Barcelona, Madrid, Valencia

2021-08-10

Recruiting

Effect of Continued Nutritional Support at Hospital Discharge on Mortality, Frailty, Functional Outcomes and Recovery

NCT04926597Malnutrition

Philipp Schuetz

Not applicable

1,200

Barcelona, Getafe, León, Madrid, Málaga, Valladolid

2021-08-05

Active, closed

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

NCT04960709Muscle Invasive Bladder Cancer

DrugsEnfortumab Vedotin·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

712

Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Pamplona, Seville

2021-08-05

Recruiting

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma

Pierre Fabre Medicament

Phase 1

400

Barcelona, Madrid, Málaga, Seville, Valencia, Las Palmas de Gran Canaria

2021-08-04

Active, closed

Pulmonary Embolism International THrOmbolysis Study-3

NCT04430569Pulmonary Embolism

DrugAlteplase

Assistance Publique - Hôpitaux de Paris

Phase 3

800

Badalona, Barcelona, Cartagena, Galdakao, Madrid, Seville, Valencia

2021-08-04

Recruiting

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

NCT04939610Solid Tumor

Drug177Lu-FAP-2286

Novartis Pharmaceuticals

Phase 1/2

222

A Coruña, Badalona, Madrid

2021-07-30

Active, closed

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

NCT07217184Multiple Myeloma

DrugsBelantamab mafodotin·Isatuximab

GlaxoSmithKline

Phase 1/2

Madrid, Pozuelo de AlarcOn Madr

2021-07-29

Recruiting

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

NCT04817618C3G

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

Barcelona, Port de Sagunt, Madrid, Málaga, Seville

2021-07-28

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04910568Multiple Myeloma

DrugsCevostamab·Pomalidomide·Tocilizumab·Daratumumab

Genentech, Inc.

Phase 1

186

Barcelona, Madrid

2021-07-26

Active, closed

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

NCT04862286Psoriasis

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

132

Esplugues de Llobregat, Madrid, Pontevedra

2021-07-24

By invitation

Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies

NCT04933721Hereditary Angioedema, HAE

DrugBerotralstat

BioCryst Pharmaceuticals

Phase 3

139

Madrid

2021-07-23

Active, closed

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

NCT05101148Neurofibromatosis Type 1

DrugSelumetinib

AstraZeneca

Phase 1

Barcelona, Madrid

2021-07-21

Active, closed

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

NCT04908189Psoriatic Arthritis

DrugsApremilast·Deucravacitinib

Bristol-Myers Squibb

Phase 3

729

Barcelona, Madrid, Santander, Valencia

2021-07-15

Active, closed

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

NCT04657289Neovascular Age-related Macular Degeneration (nAMD)

DrugRanibizumab

Hoffmann-La Roche

Phase 3

451

L'Hospitalet de Llobregat, San Cugat Del Valles, Majadahonda, Pamplona, Oviedo, Barcelona, Córdoba, Madrid

2021-07-14

Active, closed

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

NCT04554914Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)

DrugTabelecleucel

Pierre Fabre Medicament

Phase 2

190

Barcelona, Madrid, Seville

2021-07-14

Active, closed

Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation

NCT04788888Symptomatic Severe Aortic Stenosis

Abbott Medical Devices

Not applicable

434

Madrid, Alicante, Barcelona, Seville

2021-07-13

Active, closed

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.

NCT05018286Short Bowel Syndrome

DrugApraglutide

VectivBio AG

Phase 3

158

Madrid, Seville

2021-07-13

Active, closed

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

NCT04908202Psoriatic Arthritis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

670

A Coruña, Córdoba, Madrid, Sabadell

2021-07-13

Active, closed

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

NCT04898634Prostatic Neoplasms

DrugPasritamig

Janssen Research & Development, LLC

Phase 1

216

Madrid, Málaga

2021-07-13

Recruiting

Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform

NCT04927156Intracranial Aneurysm, Brain Arterial Disease, Acute Ischemic Stroke, Peripheral Vascular Diseases

Balt Extrusion

Observational

10,000

Madrid, Oviedo, Santander, Zaragoza

2021-07-12

Recruiting

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

NCT04613921Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications

European Foundation for Study of Chronic Liver Failure

Observational

3,000

Barcelona, Madrid, Santander, Seville, Valencia

2021-07-08

Recruiting

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

NCT04803994Hepatocellular Carcinoma

DrugsTecentriq·Avastin·Atezolizumab·Bevacizumab

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 3

434

Alicante, Badajoz, Badalona, Barcelona, Cadiz, Jaén, Madrid, Málaga

2021-07-06

Active, closed

Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease

NCT05043103Advanced Parkinson Disease

Britannia Pharmaceuticals Ltd.

Observational

312

Barcelona, Madrid, Seville

2021-07-06

Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

NCT04669171Follicular Lymphoma, Marginal Zone Lymphoma

DrugsLenalidomide·Rituximab

Enterome

Phase 1/2

Barcelona, Madrid, Pamplona, Salamanca

2021-07-05

Active, closed

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer

DrugZongertinib

Boehringer Ingelheim

Phase 1

554

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Valencia

2021-07-02

Active, closed

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Abemaciclib·Ribociclib

AstraZeneca

Phase 3

315

A Coruña, Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, Sant Joan Despí

2021-06-30

Active, closed

Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS

NCT05027984Coronary Artery Disease, Coronary Disease, Ischemic Heart Disease

Centro per la Lotta Contro l'Infarto - Fondazione Onlus

Not applicable

1,425

Málaga, Madrid, Oviedo

2021-06-30

Recruiting

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

NCT04965675Chronic Migraine in Children

DrugEptinezumab

H. Lundbeck A/S

Phase 3

285

Barcelona, Seville, Sevilla, Madrid

2021-06-30

Active, closed

Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease

NCT04595266Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer

DrugsFolfox·Bevacizumab

Grupo Espanol Multidisciplinario del Cancer Digestivo

Phase 2

Barcelona, Sabadell, Madrid, Pamplona, Valencia

2021-06-29

Active, closed

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755Neoplasms, Breast

DrugNiraparib

GlaxoSmithKline

Phase 3

Barcelona, Cáceres, Córdoba, Granada, Madrid, Málaga, Santiago de Compostela, Valencia

2021-06-28

Active, closed

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

NCT04629248Primary Membranous Nephropathy

DrugsDiphenhydramine·Acetaminophen·Tacrolimus·Methylprednisolone

Hoffmann-La Roche

Phase 3

142

L'Hospitalet de Llobregat, Barcelona, Madrid, Seville

2021-06-25

Active, closed

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

NCT04895722Colorectal Cancer

DrugsPembrolizumab/Vibostolimab·MK-4830·Pembrolizumab/Favezelimab·Pembrolizumab/Quavonlimab

Merck Sharp & Dohme LLC

Phase 2

302

Santander, Barcelona, Madrid, Málaga, Pamplona, Oviedo, Valencia

2021-06-25

Active, closed

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer

DrugsAdagrasib·MFOLFOX6·Erbitux·Folfox

Mirati Therapeutics Inc.

Phase 3

461

A Coruña, Badalona, Barcelona, Córdoba, LHospitalet de Llobregat, Madrid, Pamplona, Sabadell

2021-06-24

Recruiting

WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

NCT04701684Stroke, Acute

Philips Clinical & Medical Affairs Global

Not applicable

594

Madrid, Barcelona, Girona, Seville

2021-06-23

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

NCT04802759Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

DrugsSamuraciclib·Ipatasertib·Giredestrant·Phesgo

Hoffmann-La Roche

Phase 1/2

316

Barcelona, Madrid, Valencia

2021-06-22

Active, closed

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761Breast Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 3

506

Barcelona, Bilbao (Vizcaya), Granada, Madrid, Salamanca, Santander, Santiago de Compostela-Coruña, Seville

2021-06-22

Active, closed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Taxol

Merck Sharp & Dohme LLC

Phase 3

342

Barcelona, Pozuelo de Alarcón, Madrid, Valencia

2021-06-18

Active, closed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098Arthritis, Psoriatic

DrugGuselkumab

Janssen Research & Development, LLC

Phase 3

1,054

A Coruña, Córdoba, Madrid, Málaga, Móstoles, Murcia, San Sebastián de los Reyes, Santiago de Compostela

2021-06-17

By invitation

Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

NCT04451044Coronary Artery Disease, Ischemic Heart Disease

Philips Clinical & Medical Affairs Global

Not applicable

3,212

Córdoba, León, Madrid, Santander

2021-06-17

Active, closed

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

NCT04689828Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

469

Santiago Compostela, L'Hospitalet de Llobregat, El Palmar, Pamplona, Valencia, Barcelona, Madrid, Málaga

2021-06-15

Recruiting

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

NCT04657822Sickle Cell Disease

DrugCrizanlizumab

Novartis Pharmaceuticals

Phase 4

130

Barcelona, Madrid

2021-06-10

Recruiting

PEEP in Patients With Acute Respiratory Failure

NCT04912960Acute Respiratory Failure With Hypoxia

Jesus Villar

Observational

Las Palmas de Gran Canaria, Barcelona, Madrid

2021-06-10

Active, closed

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

1,140

L'Hospitalet de Llobregat, Sabadell, Majadahonda, El Palmar, Barcelona, Madrid, Valencia

2021-06-09

Active, closed

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

NCT04877691Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

367

Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2021-06-08

Active, closed

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

NCT04703192Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma

DrugValemetostat Tosylate

Daiichi Sankyo

Phase 2

155

Barcelona, Madrid, Seville

2021-06-03

Recruiting

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

NCT04898283Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic

Drugs10,000 MG01·30,000 MG01

Inmunotek S.L.

Phase 3

180

Valladolid, Tarancón, Alcalá de Henares, Alcorcón, Madrid, Majadahonda, Murcia, Ávila

2021-05-31

Recruiting

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer

DrugsImzokitug·Pumitamig·Docetaxel·Nivolumab

Bristol-Myers Squibb

Phase 1/2

1,109

Málaga, Badalona, Barcelona, Madrid, Pamplona

2021-05-27

Active, closed

Multicenter Clinical Trial Comparing Treatment with Allogeneic Mesenchymal Cells Versus Autologous Mesenchymal Cells and Versus Active Control with Hyaluronic Acid in Patients with Knee Osteoarthritis.

NCT05086939Knee Osteoarthritis

DrugHyaluronic Acid

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León

Phase 3

124

Barcelona, Madrid, Málaga, Murcia, Pamplona, Salamanca

2021-05-26

Active, closed

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel

Daiichi Sankyo

Phase 3

490

Barcelona, Madrid, Pamplona, Santiago de Compostela, Valencia

2021-05-21

Recruiting

ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

NCT04503395Aortic Aneurysm, Abdominal

FCRE (Foundation for Cardiovascular Research and Education)

Not applicable

204

Madrid, Valladolid

2021-05-21

Active, closed

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

NCT04810078Clear Cell Renal Cell Carcinoma

DrugsNivolumab and rHuPH20·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

681

Barcelona, Madrid, Sabadell, Santander, Seville

2021-05-21

Recruiting

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

NCT04811560Acute Leukemia

DrugBleximenib

Janssen Research & Development, LLC

Phase 1/2

420

Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia

2021-05-19

Active, closed

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

NCT04762069Glioblastoma Multiforme, Adult

DrugsCCNU·Lomustine

CNS Pharmaceuticals, Inc.

Phase 2

252

Badalona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville

2021-05-18

Active, closed

The SELUTION DeNovo Study

NCT04859985Coronary Artery Disease

M.A. Med Alliance S.A.

Not applicable

3,326

Barcelona, Madrid, Vigo

2021-05-15

Active, closed

Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)

NCT04728295Parkinson Disease

InSightec

Not applicable

Madrid, Pamplona

2021-05-14

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 3

815

Palma de Mallorca, Santander, Barcelona, Majadahonda, Madrid, Toledo

2021-05-12

Active, closed

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

NCT04824092Diffuse Large B-cell Lymphoma

DrugsTafasitamab·Vincristine·Doxorubicin·Prednisone

Incyte Corporation

Phase 3

899

Badalona, Barcelona, Girona, Jerez de la Frontera, Lugo, Madrid, Pamplona, Salamanca

2021-05-11

Active, closed

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 3

893

Barcelona, Granada, Lleida, Madrid, Málaga, Pamplona, Santiago de Compostela

2021-05-10

Active, closed

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

NCT04675333Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma

DrugsEvorpacept·Cisplatin/Carboplatin·Fluorouracil·Keytruda

ALX Oncology Inc.

Phase 2

172

Barcelona, Badalona, L'Hospitalet de Llobregat, Leganés, Madrid, Málaga, Pamplona

2021-05-10

Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

NCT04614103Metastatic Non Small Cell Lung Cancer

DrugLifileucel

Iovance Biotherapeutics, Inc.

Phase 2

170

A Coruña, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Salamanca, Seville

2021-05-07

By invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

NCT04848506Symptomatic Hypertrophic Cardiomyopathy (HCM)

DrugAficamten

Cytokinetics

Phase 2/3

900

A Coruña, Barcelona, Madrid, Málaga, Palma, Pontevedra, Salamanca, Seville

2021-05-06

Active, closed

Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation

NCT04818502Mitral Valve Regurgitation

Abbott Medical Devices

Observational

200

Madrid

2021-05-04

Active, closed

Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19

NCT04547257COVID-19

ExThera Medical Corporation

Not applicable

Barcelona, Madrid

2021-05-04

Active, closed

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

NCT04660344Muscle-invasive Bladder Cancer

DrugsTecentriq·Atezolizumab

Hoffmann-La Roche

Phase 3

761

Sabadell, Santander, Córdoba, Donostia / San Sebastian, Barcelona, Madrid, Seville, Valencia

2021-05-03

Recruiting

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

NCT04855656Advanced Solid Tumor

DrugsCamonsertib·Lunresertib

Debiopharm International SA

Phase 1

464

Madrid, Navarra

2021-04-30

Recruiting

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

NCT04752774Spasticity

DrugsDysport·Corabotase

Ipsen

Phase 1/2

240

A Coruña, Barcelona, Huelva, Madrid, Santiago de Compostela, Seville, Vigo

2021-04-29

Active, closed

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

NCT04868877Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

DrugsBispecific·Tagrisso·Osimertinib

Merus B.V.

Phase 1/2

194

Barcelona, Madrid, Pamplona, Valencia

2021-04-28

Active, closed

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

NCT04784715Breast Cancer; HER2-positive; Metastatic

DrugsPertuzumab·Trastuzumab deruxtecan·Trastuzumab

AstraZeneca

Phase 3

1,157

Alicante, Barcelona, Madrid, Majadahonda, Seville

2021-04-26

Recruiting

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

NCT04883905Acute Hepatic Porphyria

Alnylam Pharmaceuticals

Observational

150

Madrid

2021-04-26

Active, closed

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

NCT04770896Unresectable Hepatocellular Carcinoma

DrugsSorafenib·Tecentriq·Lenvatinib·Atezolizumab

Hoffmann-La Roche

Phase 3

557

Palma de Mallorca, Santiago de Compostela, Pamplona/iruña, Córdoba, Madrid, Valencia, Zaragoza

2021-04-26

Recruiting

RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis

AgNovos Healthcare, LLC

Not applicable

2,400

Barcelona, Valladolid, Bilbao, Galdakao, Jaén, Madrid, Manresa, Sabadell

2021-04-24

Active, closed

DiamondTemp Global Registry

NCT04735016Arrhythmia

Medtronic Cardiac Ablation Solutions

Observational

545

Barcelona, Madrid

2021-04-22

Recruiting

Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics

NCT05761080Laparoscopic Appendectomy, Complicated Appendicitis, Periappendicular Abscess

DrugMaximum

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Phase 4

772

Barcelona, Córdoba, Lleida, Madrid, Seville, Badalona, Esplugues de Llobregat, Girona

2021-04-22

Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

NCT04752722Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer

DrugPhase 2

enGene, Inc.

Phase 1/2

350

Barbera Del Valles, Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Santander

2021-04-22

Active, closed

Rectal Tumor Resection Using the UNI-VEC Multichannel Transanal Access Device

NCT06286956Rectal Polyp, Rectal Polyps, Rectal Lesion, Sessile Colonic Polyp

Vecmedical Spain, S.L.

Not applicable

Barcelona, Terrassa, A Coruña, Lugo, Vigo, Madrid, Murcia, Gijón

2021-04-19

Active, closed

Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy

NCT04758533Diffuse Intrinsic Pontine Glioma, Medulloblastoma, Childhood, Recurrent

Hospital Infantil Universitario Niño Jesús, Madrid, Spain

Phase 1/2

Madrid

2021-04-19

Active, closed

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

NCT04589650PIK3CA-related Overgrowth Spectrum (PROS)

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2

236

Esplugues, Madrid

2021-04-19

Recruiting

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

NCT04641247Ovarian Neoplasms, Breast Neoplasms

DrugNiraparib

GlaxoSmithKline

Phase 2

Madrid

2021-04-16

Active, closed

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma

DrugsTafasitamab·Lenalidomide·Rituximab

Incyte Corporation

Phase 3

654

A Coruña, Alicante, Badalona, Barcelona, Burgos, Gijón, L'Hospitalet de Llobregat, Madrid

2021-04-15

Recruiting

Tendyne European Experience Registry

NCT04898335Mitral Regurgitation

LMU Klinikum

Observational

400

Madrid, Valladolid, Vigo

2021-04-15

Recruiting

Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

NCT04159103Propionic Acidemia

DrugMRNA-3927

ModernaTX, Inc.

Phase 1/2

Esplugues de Llobregat, Barakaldo, Madrid, Seville

2021-04-15

Active, closed

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

NCT04736706Carcinoma, Renal Cell

DrugsPembrolizumab/Quavonlimab·Belzutifan·Lenvatinib·Keytruda

Merck Sharp & Dohme LLC

Phase 3

1,688

Santander, Barcelona, Girona, Madrid, Málaga

2021-04-14

Active, closed

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

NCT04794699Solid Tumor

DrugsIDE397·Sacituzumab Govitecan

IDEAYA Biosciences

Phase 1

169

Madrid, Valencia

2021-04-14

Active, closed

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

NCT04527380Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis

DrugsIxekizumab·Adalimumab

Eli Lilly and Company

Phase 3

101

Esplugues de Llobregat, Madrid, Málaga, Seville, Valencia

2021-04-13

Recruiting

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

NCT04855435Advanced Solid Tumor, Uveal Melanoma, Metastatic, Cutaneous Melanoma

MonTa Biosciences ApS

Phase 1

106

Barcelona, Madrid, Valencia

2021-04-12

Active, closed

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

NCT04576156Myelofibrosis

DrugImetelstat Sodium

Geron Corporation

Phase 3

327

Alicante, Badalona, Las Palmas de Gran Canaria, Cáceres, Granada, Madrid, Málaga, Zaragoza

2021-04-12

Active, closed

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

DrugsPelabresib·Ruxolitinib

Novartis Pharmaceuticals

Phase 3

430

Oviedo, Badalona, Barcelona, Cáceres, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca

2021-04-09

Active, closed

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255Lymphoma, Mantle-Cell

DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib

Loxo Oncology, Inc.

Phase 3

500

Málaga, Barcelona, L'Hospitalet de Llobregat, Pamplona, Palma de Mallorca, Madrid, Valencia

2021-04-08

Active, closed

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

NCT04802356Multiple Myeloma

DrugsBelantamab mafodotin·Bortezomib·Lenalidomide·Dexamethasone

PETHEMA Foundation

Phase 2

Palma de Mallorca, Santander, Salamanca, Santiago de Compostela, Madrid, Gijón, Valencia, Las Palmas de Gran Canaria

2021-04-07

Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia

DrugNemtabrutinib

Merck Sharp & Dohme LLC

Phase 2

490

L'Hospitalet de Llobregat, Salamanca, A Coruña, Alicante, Barcelona, Madrid

2021-04-05

Active, closed

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

NCT04675294Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma

DrugsEvorpacept·Keytruda·Pembrolizumab

ALX Oncology Inc.

Phase 2

189

Barcelona, Madrid, Málaga, Pamplona

2021-04-02

Active, closed

MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT)

NCT05184426Transplant Failure, Heart Transplant Rejection, Antibody-mediated Rejection

Juan Francisco Delgado Jimenez

Observational

Majadahonda, Madrid

2021-04-01

Recruiting

BoStOn SCientific Rhythm MAnagemenT REgiStry

NCT04823663Cardiac Disease

Boston Scientific Corporation

Observational

12,500

Madrid, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Zaragoza

2021-03-31

Active, closed

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

NCT04954001Neurofibromatosis 1, Plexiform Neurofibroma, NF1

DrugLuvometinib

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 1/2

160

Barcelona, Madrid

2021-03-26

Recruiting

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT04772079Plaque Psoriasis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

153

Alicante, Barakaldo, Esplugues de Llobregat, Las Palmas de GC, Madrid

2021-03-23

Active, closed

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

NCT04817007Myelofibrosis

DrugsBMS-986158·Fedratinib·Ruxolitinib

Bristol-Myers Squibb

Phase 1/2

216

Badalona, Santander, Madrid, Salamanca, Valencia

2021-03-22

Active, closed

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04691804Metastatic Castration-Resistant Prostate Cancer (mCRPC)

DrugFluzoparib

Jiangsu HengRui Medicine Co., Ltd.

Phase 3

496

Castellon, Barcelona, Córdoba, Girona, Madrid, Málaga, Seville, Valencia

2021-03-18

Active, closed

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

NCT04562870Myelofibrosis

DrugSelinexor

Karyopharm Therapeutics Inc

Phase 2

112

Madrid

2021-03-17

Active, closed

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

NCT04586010Relapsing Multiple Sclerosis

DrugsFenebrutinib·Teriflunomide

Hoffmann-La Roche

Phase 3

746

L'Hospitalet de Llobregat, Pozuelo de Alarcón, EL Palmar (EL Palmar), Vigo, Barcelona, Madrid, Málaga, Seville

2021-03-17

Active, closed

Atrasentan in Patients With Proteinuric Glomerular Diseases

NCT04573920IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease

DrugAtrasentan

Novartis Pharmaceuticals

Phase 2

103

Port de Sagunt, Barcelona, Lugo, Madrid, Majadahonda

2021-03-15

Active, closed

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

NCT04639050Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 1/2

241

Sant Cugat del Vallès, Donostia / San Sebastian, Barcelona, Madrid, Valencia

2021-03-15

Active, closed

Investigating Bone Cement With or Without Inossia® Cement Softener for Vertebral Compression Fractures

NCT05676320Vertebral Compression Fracture

Inossia AB

Not applicable

203

Madrid, Medina del Campo, Valladolid

2021-03-11

Active, closed

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT04666038Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsIdelalisib·Truxima·Pirtobrutinib·Bendamustine

Loxo Oncology, Inc.

Phase 3

238

L'Hospitalet de Llobregat, Toledo, Santiago de Compostela, Pozuelo de Alarcón, Madrid, Albacete, Barcelona, Cáceres

2021-03-09

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Durvalumab

AstraZeneca

Phase 1

304

Badalona, Madrid, Seville, Valencia

2021-03-09

Recruiting

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

NCT04777994Advanced Solid Tumor Cancer

Calico Life Sciences LLC

Phase 1

248

L'Hospitalet de Llobregat, Madrid

2021-03-09

Active, closed

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

NCT04486378Colorectal Cancer Stage II, Colorectal Cancer Stage III

DrugAutogene cevumeran

BioNTech SE

Phase 2

327

A Coruña, Ávila, Badalona, Barcelona, Córdoba, Madrid, Majadahonda, Málaga

2021-03-08

Recruiting

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

NCT04710576Chronic Graft-versus-host-disease

DrugAxatilimab

Syndax Pharmaceuticals

Phase 2

296

Seville, Barcelona, Donostia / San Sebastian, Granada, Madrid, Majadahonda, Salamanca, Santander

2021-03-04

Recruiting

sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.

NCT04766866Preeclampsia, Intrauterine Growth Restriction, Maternal Hypertension, Neonatal Outcome

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Not applicable

9,132

Badalona, Las Palmas de Gran Canaria, El Palmar, Barcelona, Madrid, Palma de Mallorca, Valencia, Zaragoza

2021-03-02

Active, closed

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

NCT04608318Chronic Lymphoid Leukemia

DrugsVenclyxto·Ibrutinib·Obinutuzumab·Venetoclax

German CLL Study Group

Phase 3

897

Badalona, Barcelona, Madrid, Málaga, Oviedo, Salamanca, Santander, Seville

2021-03-01

Active, closed

Effectiveness of Radial Pressure Waves Therapy in the Treatment of Non-Specific Neck Pain (rPWT)

NCT04758065Neck Pain

Universidad Pontificia Comillas

Not applicable

Ciempozuelos, Madrid

2021-03-01

Active, closed

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis

DrugLuspatercept

Celgene

Phase 3

313

Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Palma de Mallorca, Salamanca, Santiago de Compostela, Seville

2021-02-25

Active, closed

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

NCT04586231Carcinoma, Renal Cell

DrugsBelzutifan·Cabozantinib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

747

A Coruña, Madrid, Barcelona, Seville

2021-02-25

Active, closed

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung

DrugsTNO155·Opnurasib·Tislelizumab

Novartis Pharmaceuticals

Phase 1/2

344

Santiago Compostela, L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia

2021-02-24

Active, closed

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

NCT04721015Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)

DrugsOsimertinib·Docetaxel

AbbVie

Phase 1

Barcelona, Madrid, Majadahonda, Málaga

2021-02-23

Active, closed

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

NCT04644575Hemophilia A

DrugEfanesoctocog alfa

Bioverativ, a Sanofi company

Phase 3

261

Esplugues de Llobregat, Madrid

2021-02-23

Active, closed

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm

DrugRuxolitinib

Incyte Corporation

Phase 1

140

Badalona, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca

2021-02-23

Active, closed

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04408638Diffuse Large B-cell Lymphoma

DrugsRituxumab·Glofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

270

Barcelona, Madrid, Seville, Valencia

2021-02-23

Active, closed

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

NCT04657081Acute Myeloid Leukemia

DrugsDecitabine·Venclexta·Venetoclax

Taiho Oncology, Inc.

Phase 1/2

101

Oviedo, L'Hospitalet de Llobregat, Pamplona, Madrid, Salamanca, Valencia

2021-02-09

Active, closed

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

NCT04229979Acute Myeloid Leukemia

DrugsGm-Csf·Sargramostim·Ara-C·Decitabine

Sellas Life Sciences Group

Phase 3

127

Cáceres, Córdoba, Madrid, Oviedo, Pamplona, Salamanca, Seville, Valencia

2021-02-08

Active, closed

ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

NCT05388708Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation

University of Michigan

Observational

550

Barcelona, Madrid

2021-02-04

Recruiting

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT04901936Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria

DrugPegcetacoplan

Apellis Pharmaceuticals, Inc.

Phase 2

Barcelona, Madrid

2021-02-04

Active, closed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

NCT04431726Severe Hemophilia A

DrugEmicizumab

Hoffmann-La Roche

Phase 3

Esplugues de Llobregat, Madrid, Seville

2021-02-04

Recruiting

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

NCT03127267Amyotrophic Lateral Sclerosis

DrugsMasitinib·Riluzole

AB Science

Phase 3

495

Alicante, Barcelona, Madrid, Santiago de Compostela, Valencia

2021-02-02

Active, closed

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

NCT04649359Multiple Myeloma

DrugElranatamab

Pfizer

Phase 2

187

Madrid, Valencia

2021-02-02

Active, closed

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

277

Seville, Badalona, Majadahonda, Barcelona, Madrid, Málaga, Zaragoza

2021-02-02

Active, closed

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04612751Advanced or Metastatic NSCLC

DrugsSabestomig·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 1

155

A Coruña, Badalona, Barcelona, Madrid, Seville

2021-02-02

Recruiting

First-In-Human Clinical Study for Treatment of Severe Mitral Valve INsufficiency With Epygon™ TRanscatheter Mitral VAlve System

NCT04775108Mitral Valve Regurgitation

Epygon

Not applicable

Badalona, Barcelona, Madrid, Murcia, Seville

2021-02-01

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04634552Hematological Malignancies

DrugTalquetamab

Janssen Research & Development, LLC

Phase 2

510

Badalona, Barcelona, Madrid, Murcia, Pamplona, Pozuelo de Alarcón, Salamanca, Santander

2021-02-01

Recruiting

Pediatric In-Hospital Cardiac Arrest International Registry (PACHIN)

NCT04675918Cardiac Arrest, Pediatric ALL, In-hospital Cardiac Arrest

Jimena del Castillo

Observational

500

Madrid

2021-02-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/madrid?page=5

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,046 of those studies with a site in Madrid.

How many clinical trials are recruiting in Madrid?

1,554 of the 3,046 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 117 have not yet opened recruitment, 1,309 are active but closed to new participants, and 66 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.